Michele Caraglia – Cesintell

michele.caraglia@unicampania.it

29 December 2017-present. Full Professor of Biochemistry, Department of Precision Medicine, University of Campania Luigi Vanvitelli

from 1st July 2012- Adjunct Associate Professor- Sbarro Institute for Cancer Research and Molecular Medicine, Center of Biotecnology Temple University Philadelphia, PA, U.S.A.

1.01.2019 -present President of the Italian Cell Cultures Association AICC

1.01.2015-31.12.2018 Vice-president and Treasurer of the Italian Cell Cultures Association AICC

24.10.2010 -31.12.2014 Secretary and Treasurer of the Italian Cell Cultures Association AICC

2007-2010 Member of the Scientific Board of the Italian Cell Cultures Association AICC

1997-present – Professor at the School for the Specialty in Biochemistry and Clinical Chemistry of the Second University of Naples.

1 November 2011-present. Associate Professor of Biochemistry, Department of Biochemistry and Biophysics, University of Campania Luigi Vanvitelli

1 November 2014- present Medical Responsible of the service of nucleotide sequencing in the Unit of Advanced Cytometry at the Policlinico Hospital of the Second University of Naples.

3rd June 2008- 31 October 2011- Assistant Professor of Clinical Biochemistry and Molecular Biology, Department of Biochemistry and Biophysics, Second University of Naples

1 Sept. 2004-3rd June 2008 Senior Investigator of the Experimental Pharmacology Unit of the National Institute of Tumours of Naples. Potentiation of the antitumour activity of cytokines and of inhibitors of isoprenylation – overcoming the escape mechanisms in prostate cancer

2002-2004- Guest researcher at the Department of Biochemistry and Biophysis, Second University of Naples, Naples, Italy. Potentiation of the antitumour activity of cytotkines and of inhibitors of isoprenylation – overcoming the escape mechanisms in prostate cancer.

1997-1998- Guest researcher at the University Tor Vergata, Biology Dept. Study of the effects of cytokines on the protein synthesis – escape mechanisms.

1991-1992 – Guest researcher in the Laboratory of IIGB, CNR, Naples. Study of the synthesis of EGF-R protein in cells exposed to IFNa or 8ClcAMP in SCC.

1995-1996- Guest researher in the Leukemia Unit of CRO, Aviano, Italy. Study of the effects of cytotoxic drugs on EGFR, transferrin receptor and NGFR expression.

Curriculum Vitae

Michele Caraglia

Mother tongue(s) Other language(s)

English

ADDITIONAL INFORMATION

Italian

Curriculum Vitae Replace with First name(s) Surname(s)

EDUCATION AND TRAINING Replace with dates (from – to)

2015- National Scientific Qualifications as full professor in Biochemistry 2014- National Scientific Qualifications as full professor in Molecular Biology

1999-2002- PhD degree in Cellular Biochemistry at the Department of Biochemistry and Biophysicssis, Second University of Naples, Naples, Italy. Potentiation of the antitumour activity of cytotkines and of inhibitors of isoprenylation – overcoming the escape mechanisms in SCC.

1990-1994 Expecialization in Oncology with magna cum laude, University Federico II of Naples, Italyaly. Study of the activation status of ras in response to pharmacological treatments in SCC – escape mechanisms.

1990- Degree in Medicine with magna cum laude, University Federico II of Naples, Italy. Experimental degree thesis on the study of EGF-R expression modulation induced by IFNa in human squamous cancer cells (SCC).

UNDERSTANDING SPEAKING WRITING Listening Reading Spoken interaction Spoken production

C2 C2 C2 C2 C2

Editor in Chief

– Translational Medicine Research
– The Open Cancer Immunology Editorial Board Member of peer reviewed international journals – Journal Experimental and Clinical Cancer Research – Recent Patents on Anti-Cancer Drug Discovery
– Journal of Cellular Biochemistry
– Nanomedicine – Journal of Cellular and Molecular Medicine
– Journal of Interferon and Cytokine Research
– International Journal of Oncology
– Current Cancer Drug Targets
– Expert Opinion on Biological Therapy
– Cancer Biology & Therapy
– In vivo
– Cancer Cell International
– Recent Patents in Anti-Cancer Drug Discovery – World Journal of Experimental Medicine
– The Open Cancer Journal
– Open Surgical Oncology Journal

Page 2 / 42

Curriculum Vitae Michele Caraglia

AWARDS AND PERSONAL GRANTS

27/10/1992 – Annual grant from “Fondazione Marinelli” for the research in Molecular Oncology.

20/12/1993 – Three year grant (1993-1996) form the Italian Association for Cancer Research for a Research on the Homeostatic mechanisms of tumour cells in response to cytokines.

1996 – First prize from the Italian Association of Medical Oncology for the best communication presented at the XIV National Congress of the Association in Milan.

2002- First Prize for the best Communication presented at the Scientific Meeting of the School of Medicine of the Second University of Naples, Naples, Italy.

2008- First Prize for the best Communication presented at the National Meeting of Southern Italy Oncology Association.

2020- Prize from the International Human Rights Commission (IHC) for the studies on a new system of self- administration rhino-pharyngeal swab for the determination of COVID-19 infection.

FINANCIAL SUPPORTS AND COOPERATIONS

2004-2005 Financial support received from Novartis for the research project entitled: EFFECTS OF ZOLEDRONATE ON EGF-DEPENDENT SIGNAL TRANSDUCTION AND ON APOPTOSIS OF PANCREAS AND PROSTATE ADENOCARCINOMA CELLS (30.000,00 euros).

2005 Financial support received from Janssen for the research project entitled:: NEW INTEGRATED THERAPEUTIC STRATEGIES IN THE TREATMENT OF HORMONE-REFRACTORY PROSTATE ADENOCARCINOMA (12.000,00 euros)

2005-2007 Financial support received from Italian Association for Cancer Research for the research project entitled: INHIBITION OF ISOPRENYLATION AND OF ACETYLATION AS A NEW STRATEGY FOR THE THERAPY OF PROSTATE CANCER (110.000,00 euros).

2005-2007 Financial support received from Italian Ministry of Health for a project on the study of isoprenylation inhibition in prostate cancer (32.000,00 euros).

2008- Financial support received from Novartis Oncology (10000 euro) for a project entitled: Evaluation of the biological effects of the combination between octreotide and sorafenib in patients with hepatocellular carcinoma.

2010- Financial support received from Novartis Oncology (15000 euro) for a project entitled: Development of a new formulation of Zoledronic acid encapsulated in sterically stabilized and functionalized liposomes: Preparation, characterization, preclinical toxicity and activity.

2010-2012 Financial Support received by governative authorities of Regione Campania for the realization of “Hauteville” Public Laboratory for a project entitled: “Optimization of the pharmacokinetic profile of anti-tumour agents through nanotechnology and definition of new diagnostic markers and therapeutic targets” (830.000,00

Curriculum Vitae Replace with First name(s) Surname(s) euros).

2010- Chief of operative unit in a project of relevant scientific and technological interest of the Second University of Naples entitled: “Optimization of the anti-tumour efficacy of a mixture of antibodies produced by a single cloned cell and raised against tyrosine kinase receptors of different growth factors involved in the progression of colo-rectla cancer” Global grant of 130.000 euro.

2010- Financial support received from Novartis Oncology (100000 euro) for 2010 for a project entitled “Evaluation of the in vitro and in vivo anti-angiogenic effects of denosumab”.

10/2011-10/2013 Financial support received from Italian Ministry for Education and Scientific Research for a Program of Scientific Research of National Relevance (PRIN) entitled “Nanotechnological development of target-based and cytotoxic agents in the treatment of tumours: new strategies based upon biological rationales” (247926.00 euro).

2011-2013 Financial support received from Italian Association for Cancer Research for the research project entitled (50.000 €/year for 3 years): Liposome-encapsulating zoledronic acid: a new experimental therapeutic for the treatment of brain tumours.

2012-2017 Financial support received from FIRB (340.000 euro) “Technology Platforms for advanced development of new biomarkers and molecular targets in vectors nano technology for diagnosis and therapy of human cancer”

2012-2015 Financial support for the Special Program Molecular Clinical Oncology 5 per mille received from Italian Association for Cancer Research for a project entitled: “A research platform for miRNA-based treatment of multiple myeloma and chronic lymphocytic leukemia” (450.000 euro).

03/2014-03-2017 Financial Support received by governative authorities of Regione Campania for the building up of the Biotechnological Network in Campania for a project entitled “Innovative Therapies in Chronic Inflammatory, metabolic, Neoplastic and Geriatric diseases- TIMING” (130.000 euro)

ORGANIZATION OF CONGRESSES AND MEETINGS

Member of the Scientific Committee of the annual Meeting of the Associazione Italiana Colture Cellulari “APOPTOSI TRA FISIOLOGIA E PATOLOGIA” Napoli 9-10 dicembre 2004 Facoltà di Medicina e Chirurgia – Seconda Università di Napoli (SUN), Aula della Presidenza, via Costantinopoli n. 108, Napoli. 10 Dicembre 2004 – Titolo della relazione: “Nuovi approcci di terapia antitumorale basati sull’induzione di apoptosi attraverso l’inibizione dell’attività di ras con famaci interferenti con i processi di prenilazione”.

Co-Director and Chair Session of course ECM entitled “Nuovi farmaci agenti su specifici bersagli molecolari nel trattamento delle neoplasie umane” Istituto Nazionale dei Tumori Fondazione “G. Pascale” di Napoli. Aula “Romolo Cerra”. Napoli, 22-24 June 2005.

Co-Director e Chair Session of the 20th National Annual Meeting of the Associazione Italiana Colture Cellulari “NUOVE VEICOLAZIONI FARMACOLOGICHE E PIATTAFORME TECNOLOGICHE PER LA DIAGNOSI E TERAPIA DI TUMORI E MALATTIE CRONICO-DEGENERATIVE”- Napoli: INT Fondazione “G. Pascale”, Aula Magna “Romolo Cerra” 6-7 December 2007

Member of the Scientific Committee and Chair of the Annual National Meeting of the Associazione Italiana Colture Cellulari entitled ”La cellula dalla regolazione trascrizionale e post-trascrizionale alla terapia cellulare ” Bologna 26-28 November 2008

Co-Direttore e Chair of meeting entitled “L’innovazione delle terapie “intelligenti” in oncologia: dalla target based alle nanotecnologie.” Aula Magna della Presidenza della Facoltà di Medicina della Seconda Università di Napoli. 2-3 April 2009.

Co-Director and Chair of the Congress entitled: “Research Workshop in Translational Oncology” Continental Terme Hotel, Ischia, 23 May2009

PUBLICATIONS

Curriculum Vitae Michele Caraglia

Member of the Scientific Committee and Chair of the Annual Meeting of the Associazione Italiana Colture Cellulari entitled ”La morte della cellula implicazioni fisiopatologiche e terapeutiche” Firenze 2-4 Dicember 2009

Co-Director and Chair of International Congress entitled: “New therapeutical targets and molecular markers in cancer management” Ischia, Terme Continental Hotel, 26th May 2010

Member of the Scientific Committee and Chair of 23rd Annual National Meeting of the Associazione Italiana Colture Cellulari entitled: “Nanotecnologie e veicolazione di farmaci” Istituto Nazionale dei Tumori di Milano – 24-26 November 2010.

Co-Director and Chair of the workshop entitled: “La terapia dei tumori e metastasi cerebrali: dalla ricerca di base alla pratica clinica” Napoli, Aula di presidenza Seconda Università di Napoli – 27-28 September 2011

Member of the Scientific Committee and Chair of the 24th Annual National Meeting of the Associazione Italiana Colture Cellulari entitled : “Struttura, modificazioni epigenetiche e meccanismi di riparo del DNA come bersaglio per terapie innovative antitumorali” hold at the Istituto Nazionale dei Tumori “Regina Elena” di Roma. – 21-23 November 2011

Organizer and Director of the “1st workshop on advanced cell culture systems in tumour biology: invasion, migration and angiogenesis” at the Department of Biochemistry and Biophysics of the Second University of Naples in Naples from 11th at 15th June 2012

(TOTAL IMPACT FACTOR: 10000; H INDEX (SCHOLAR: 70; SCOPUS: 59; ISI WEB: 55)

1. A. Budillon, P. Tagliaferri, M. Caraglia, M.R. Torrisi, N. Normanno, S. Iacobelli, G. Palmieri, M.P. Stoppelli, L. Frati, A.R. Bianco. “Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells.”
Cancer Research, 51:1294-1299, 1991. IF 7.7

2. P. Correale, A. Procopio, L. Celio, M. Caraglia, G. Genua, V. Coppola, S. Pepe, N. Normanno, I. Vecchio, G. Palmieri, S. Montagnani, P. Tagliaferri, A. R. Bianco. “Phorbol 12-Myristate 13-Acetate induces resistance of human melanoma cells to natural- killer- and lymphokine- activated-killer-mediated cytotoxicity.”
Cancer Immunology Immunotherapy, 34:272-278, 1992. IF 3.5

3. S. Montagnani, G. Giordano-Lanza, E. Di Vaia, R. Vitelli, R. Spera, A. R. Bianco, M. Caraglia, P. Tagliaferri, P. Correale. “Phorbol Myristate Acetate (PMA) induces differentiations and morphological changes in a human adenocarcinoma cell line.”
Recent Advances in Cellular Molecular Biology, Paris, September 1-7, Peeters Press, Leuven, Belgium; 1: 243-247, 1992.

4. P. Correale, P. Tagliaferri, A. Camera, M. Caraglia, V. Coppola, A. Pinto, L. Del Vecchio, B. Rotoli, A. R. Bianco. “CD10/CALLA and adhesion factor expression is predictive for LAK sensitivity of adult B-lineage ALL cells in vitro.” In: The Year in Immunology, Terhost C., Malavasi F., Albertini A. (eds.); Karger, Basel; 7: 90-95, 1993.

5. M. Caraglia, P. Correale, G. Genua, S. Pepe, S. Del Vecchio, G. Esposito, A. R. Bianco, P. Tagliaferri. “Epidermal growth factor (EGFR) and transferrin (TRFR) receptor upregulation is induced by arabinoside cytosine (ARA-C) on human tumor cells.”
Cancer Detection and Prevention, 17: 337-338, 1993. IF 1.4

6. M. Caraglia, P. Tagliaferri, P. Correale, G. Genua, S. Pepe, A. Pinto, S. Del Vecchio, G. Esposito, A. R. Bianco. “Cytosine arabinoside

increases the binding of 125I-labelled epidermal growth factor and 125I-transferrin and enhances the in vitro targeting of human tumour cells with anti- (growth factor receptor) mAb.”
Cancer Immunology Immunotherapy, 37:150-156, 1993. IF 3.5

7. P. Correale, M. Caraglia, A. Procopio, M. R. Marinetti, R. Guarrasi, A. Fabbrocini, A. R. Bianco, P. Tagliaferri. “Transmembrane ion flux modifiers verapamil and ouabain modulate cytotoxic effects of extracellular ATP on human tumor cells in vitro.”
International Journal of Oncology, 3: 847-851, 1993. IF 3.1

Page 5 / 42

Curriculum Vitae Replace with First name(s) Surname(s)

8. M. Caraglia, A. Pinto, P. Correale, V. Zagonel, G. Genua, A. Leardi, S. Pepe, A. R. Bianco, P. Tagliaferri. “5-Aza-2′-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells.”
Annals of Oncology, 5:269-276, 1994. IF 4.4

9. P. Correale, M. Caraglia, S. Pepe, B. Ricciardi, C. Barile, S. Montagnani, R. Pacelli, A. R. Bianco, P. Tagliaferri. “Phorbol-12-myristate 13- acetate (PMA) induces neuroendocrine differentiation and reverses doxorubicin resistance of human colon carcinoma cells in vitro. International Journal of Oncology, 4: 423-427, 1994. IF 3.1

10. P. Tagliaferri, P. Correale, M.Mottola, G. de Simone, A. Rea, R. Ascione, A. Morabito, E. Matano, V. Montesarchio, M. Caraglia, G. Tortora, F. Ciardiello, C. Barile, G. Palmieri, A.R.Bianco. “Cardiovascular monitoring of drug-resistant lymphoma patients treated with EPOCH chemotherapy plus high dose verapamil in continuous infusion”.
Oncology Reports 1:341-44, 1994. IF 1.4

11. P. Tagliaferri, M. Caraglia, R. Muraro, A. Budillon, A. Pinto, A. R. Bianco. “Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy.”
Anti-Cancer Drugs 5:379-393, 1994. IF 2.1

12. G. Palmieri, A. Morabito, A. Rea, M. Caraglia, P. Tagliaferri, A.R. Bianco. “Cytosine Arabinoside (Ara-C) plus Alpha-Interferon (aIFN) determine prolonged remissions in patients with aggressive non Hodgkin lymphoma partially responsive to first-line doxorubicin containing regimens.”
British Journal of Haematology 88: 421-423, 1994. IF 3.2

13. M. Caraglia, A. M. Libroia, S. Corradino, V. Coppola, R. Guarrasi, C. Barile, G. Genua, A. R. Bianco and P. Tagliaferri. “a-Interferon induces depletion of intracellular iron content and upregulation of functional transferrin receptors on human epidermoid cancer KB cells.” Biochemical and Biophysical Research Communications 203: 281-288, 1994. IF 3

14. P. Tagliaferri, M. Caraglia, P. Correale, C. Barile, A.R. Bianco. “Chemio-immunoterapia del melanoma umano.” Temi di Oncologia, Pyxis (Suppl. Rivista USSL N. 4); Palazzo S., Liguori V., Conforti S. (editori); 5: 83-102, 1994.

15. A. Morabito, P. Tagliaferri, A. Rea, M. Caraglia, A.R. Bianco, G. Palmieri. “Ara-C plus a-interferon: a new and effective treatment of non Hodgkin’s lymphoma.” In:

Proceedings of the XVI International Cancer Congress, Rao R.S., Deo M.G., Sanghvi L.D., Mittra I. (eds.); Monduzzi, Bologna; pp. 2623- 2626, 1994.

16. R. Pennarola, A.R. Bianco, P. Tagliaferri, M. Caraglia, R. Guarrasi, A. Di Pace, E. Pennarola. “Aspetti della sorveglianza immunologiaca anti-tumorale in soggetti esposti alle radiazioni ionizzanti”
Archivio di Scienze del Lavoro, Vol. X, n. 2, 1994.

17. P. Correale, M. Giuliano, P. Tagliaferri, R. Guarrasi, M. Caraglia, M.R. Marinetti, T. Iezzi, A.R Bianco, A. Procopio. “Role of Adenosine 5′ Triphosphate activated (LAK) killing of human tumor cells”.
Res. Commun. Molecular Pathology and Pharmacology 87: 67-69, 1995. IF 1.2

18. F. Ciardiello, V. Damiano, C. Bianco, G. di Isernia, A. Ruggiero, M. Caraglia, P. Tagliaferri, J. Baselga, J. Mendelsohn, A. R. Bianco and G. Tortora. “Cooperative antiproliferative effects of 8-Cl-cAMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells.”
Clinical Cancer Research 1: 161-167, 1995. IF 5.6

19. P. Correale, M. Caraglia, A. Fabbrocini, R. Guarrasi, S. Pepe, V. Patella, G. Marone, A. Pinto, A.R. Bianco and P Tagliaferri. “Bryostatin 1 enhances lymphokine activated killer (LAK) sensitivity and modulates b1 integrin profile of cultered human tumor cells”.

Anti-Cancer Drugs 6:285-290, 1995. IF 2.1

20. M. Caraglia, A. Leardi, S. Corradino, F. Ciardiello, A. Budillon, R. Guarrasi, A.R. Bianco, P. Tagliaferri “a-Interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells”
International Journal of Cancer 61: 342-347, 1995. IF 4.4

21. P. Tagliaferri, E. Matano, A. Rea, M. Famiani, F. Ciardiello, G. Tortora, V. Montesarchio, A. Morabito, M. Caraglia, M. De Laurentiis, S. De Placido, G. Palmieri, A.R. Bianco “Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin’s lymphoma patients non-elegible for standard cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) combination”
Oncology Reports 2: 365-368, 1995. IF 1.4

22. M. Caraglia, A. Passeggio, P. Tagliaferri, A. Leardi, A.R. Bianco, M.G. D’Angelo, S. Beninati, A. Abbruzzese. “Effects of interferon a2- recombinant (IFNa) on the expression of epidermal growth factor receptor (EGF-R) and on eukaryotic initiation factor-5A (eIF-5A) synthesis in human epidermoid cancer KB cells.”
Italian Journal of Biochemistry, 45/1: 22-24, 1996. IF 0.1

Page 6 / 42

Curriculum Vitae Michele Caraglia

23. P. Tagliaferri, G. Tortora, R. Guarrasi, V. Damiano, A. Ruggiero, D. Morelli, M. Caraglia, R. Bianco, G. di Isernia, S. Pepe, C.L. Arteaga, B.C. Langton-Webster, A.R. Bianco and F. Ciardiello. “Differential sensitivity to non-MHC-restricted rIL-2 activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or PKA subunits”
Clinical Cancer Research, 2: 207-214, 1996. IF 5.6

24. M. Caraglia, A. Leardi, B. Ricciardi, M. de Laurentiis, M. L. Lentini Graziano, E. Matano, S. De Placido, A. R. Bianco, P. Tagliaferri “a- Interferon potentiates the growth inhibitory effects of anti-transferrin receptor monoclonal antibodies”
International Journal of Oncology, 8: 847-850, 1996. IF 3.1

25. P. Tagliaferri, P. Correale, M. Mottola, G. de Simone, V. Montesarchio, E. Matano, A. Rea, A. Morabito, M. Famiani, F. Ciardiello, G. Tortora, M. Caraglia, C. Barile, G. Palmieri and A. R. Bianco “High dose recombinant interleukin-2/Verapamil combination in advanced cancer”
European Journal of Cancer, 8 (32A): 1436-1437, 1996. IF 3.3

26. G. Palmieri, A. Morabito, A. Rea, R. Lauria, V. Montesarchio, E. Biondi, M. Caraglia, P. Tagliaferri, A.R. Bianco “Maintenance therapy with recombinant interferon alpha-2B (aIFN) in prognostically unfavourable aggressive non Hodgkin’s lymphomas (NHL)”.
Oncology Reports, 3: 733-735, 1996. IF 1.4

27. A. Passeggio, M. Caraglia, S. Beninati, A. Leardi, P. Tagliaferri and A. Abbruzzese. “Hypusine biosynthesis is correlated to ornithine decarboxylase activity in KB cells.”
Italian Journal of Biochemistry, 46 : 32-35, 1997. IF 0.1114

28. M. Caraglia, A. Passeggio, S. Beninati, A. Leardi, L. Nicolini, S. Improta, A. Pinto, A.R. Bianco, P. Tagliaferri, A. Abbruzzese. “Interferon a2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells.” Biochemical Journal, 324: 737-741, 1997. IF 4.3

29. M. Caraglia, A. Leardi, S. Improta, V. Perin, B. Ricciardi, C. Arra, P. Ferraro, A. Fabbrocini, A. Pinto, A.R. Bianco, P. Tagliaferri. “Transient exposure to cytarabine increases peptide growth factor receptor expression and tumorigenicity of melanoma cells”.
Anticancer Research, 17: 2369-2376, 1997. IF 1.4

30. P. Tagliaferri, C. Barile, M. Caraglia, R. Guarrasi, D. Morelli, B. Ricciardi, A. Martignetti, M.T. Librera, E. Matano, M. Famiani, A. Della Vecchia, G. Catalano, G. Palmieri, P. Correale, A.R. Bianco “Daily low dose subcutaneous recombinant Interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects.”
American Journal of Clinical Oncology (CCT), 21: 48-53, 1998. IF 1.7

31. P. Tagliaferri, R. Guarrasi, M. Caraglia, D. Morelli, A. Fabbrocini, P. Correale, A. R. Bianco. “Tumour cell resistance to non-MHC restricted lymphocytes: molecular mechanisms and clinical implications.”
Cancer Immunology Immunotherapy, 46:121-127, 1998. IF 3.5

32. A. LEARDI, M CARAGLIA, C. SELLERI, S. PEPE, C. PIZZI, R. NOTARO, A. FABBROCINI, S. DE LORENZO, M. MUSICÒ, A. ABBRUZZESE, A.R. BIANCO AND P. TAGLIAFERRI. “DESFERIOXAMINE INCREASES IRON DEPLETION AND APOPTOSIS INDUCED BY ARA-C ON HUMAN MYELOID LEUKEMIC CELLS.”

BRITISH JOURNAL OF HAEMATOLOGY, 102(3): 746-752, 1998. IF 3.2

33. S. Beninati, V. Gentile, M. Caraglia, A. Lentini, P. Tagliaferri, and A. Abbruzzese “Tissue transglutaminase expression affects hypusine metabolism in BALB-C 3T3 cells”
FEBS Letters, 437: 34-38, 1998. IF 3.9

34. M. Caraglia, M. Marra, G. Giuberti, A. Leardi, S. Pepe, A. Fabbrocini, S. Beninati, A. R. Bianco, P. Tagliaferri and A. Abbruzzese “Desferioxamine And Arabinoside Cytosine (Ara-C) Effects On Iron Depletion, Apoptosis And Hypusine Levels In Human Myeloid Leukemic Cells.” In: COST917 “Biogenically active amines in food”, Vol. III “Biologically active amines in food processing and amines produced by bacteria, and polyamines and tumour growth.” Bardocz, S., Koninkx, J., Grillo, M. and White, A., eds. Luxembourg, pp. 106-113, 1999.

35. P. Stiuso, G. Colonna, R. Ragone, M. Caraglia, J.W.B. Hershey, S. Beninati, and A. Abbruzzese “Structural organization of the human eukaryotic initiation factor 5A precursor and its site-directed variant LYS 50→ARG”
Amino Acids, 16: 91-106, 1999. IF 2

36. G. Lupoli, G. Vitale, M. Caraglia, M.R. Fittipaldi, A. Abbruzzese, P. Tagliaferri, A.R. Bianco “Familial non medullary thyroid carcinoma: a new clinical entity”
The Lancet,20: 637-639l, 1999. IF 10.23

37. M. Caraglia, E. Di Gennaro, D. Barbarulo, M. Marra, P. Tagliaferri, A. Abbruzzese, A. Budillon “Upregulated EGF receptors undergo to rapid internalization and ubiquitin-dependent degradation in human cancer cells exposed to 8-Cl-cAMP”

FEBS Letters, 447: 203- 209, 1999.

IF 3.9

Curriculum Vitae Replace with First name(s) Surname(s)

38. A. Budillon, E. Di Gennaro, M. Caraglia, D. Barbarulo, A. Abbruzzese and P. Tagliaferri “8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor”
British Journal of Cancer, 81: 1134-1141, 1999. IF 3.8

39. M. Caraglia, A. Abbruzzese, A. Leardi, S. Pepe, A. Budillon, G. Baldassarre, C. Selleri, S. De Lorenzo, A. Fabbrocini, G. Giuberti, G. Vitale, G. Lupoli, A. R. Bianco, and P. Tagliaferri “Interferon-a induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor” Cell Death and Differentiation, 6: 773-780, 1999.

IF 8.2

40. M. Caraglia, P. Tagliaferri, A. Budillon, and A. Abbruzzese “Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy” Advances in Experimental and Medicine Biology, Plenum Press, New York, 1999, pp 187-198.
IF 0.7

41. G. Vitale, P. Tagliaferri, M. Caraglia, E. Rampone, A.Ciccarelli, A.R.Bianco, A. Abbruzzese, G. Lupoli “Slow release lanreotide in combination with interferon-α-2b in the treatment of symptomatic advanced medullary thyroid carcinoma: an algoritmic approach to the definition of response”
Journal of Clinical Endocrinology and Metabolism, 85, 983-988, 2000. IF 5.8

42. A. Lentini, F. Autuori, P. Mattioli, M. Caraglia, A. Abbruzzese, S. Beninati “Evaluation of the efficacy of potential antineoplastic drugs on tumour metastasis by computer-assisted image analysis”
European Journal of Cancer, 36(12):1572-1577, 2000. IF 3.3

43. A. Lentini, F.Vidal-Vanaclocha, F. Facchiano, M. Caraglia, A.Abbruzzese and S. Beninati “Theophylline administration markedly reduces hepatic and pulmonary implantation of B16-F10 melanoma cells in mice”
Melanoma Research, 10: 435-443, 2000. IF 1.7

44. M. Caraglia, A. Budillon, G. Vitale, G. Lupoli, P. Tagliaferri and A. Abruzzese “Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation”
European Journal of Biochemistry 267: 3919-3936, 2000. IF 3.3

45. M. Caraglia, M. Marra, G. Giuberti, A.M. D’Alessandro, A. Budillon, S. Del Prete, A. Lentini, S. Beninati and A. Abbruzzese. “The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis”.
Amino Acids, 20, 91-104, 2001. IF 2

46. G. Vitale, M. Caraglia, A. Ciccarelli, P. Tagliaferri, A. Abbruzzese, G. Lupoli. Current approaches in the therapy of thyroid medullary carcinoma.
Cancer 91(9):1797-1808, 2001. IF 4.4

47. S. Del Prete, D. Russo, M. Caraglia, G. Giuberti, M. Marra, G. Vitale, G. Lupoli, A. Abbruzzese, E. Capasso “Percutaneous ethanol injection of autonomous thyroid nodules with a volume larger than 40 ml: three years of follow-up”.
Clinical Radiology 56(11): 895-901, 2001. IF 1.5

48. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Abbruzzese A, Lupoli G
“Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer”. British Journal of Cancer 15, 84,1586-90, 2001. IF 3.8

49. A. M. Facchiano, P. Stiuso, M. L. Chiusano, M. Caraglia, G. Giuberti, M. Marra, A. Abruzzese, G. Colonna “Homology modelling of the human eukaryotic initiation factor 5A (eIF-5A)”.
Protein Engineering 14, 881-890, 2001. IF 3.8

50. C. Pizzi, M. Caraglia, M. Cianciulli, A. Libroia, A. Fabbrocini, A. Martignetti, E. Matano, A. Contegiacomo, S. Del Prete, A. Abbruzzese, A. Martignetti, P. Tagliaferri And A. R. Bianco Low doses recombinant il-2 induces psychological changes: monitoring by minnesota multiphasic personality inventory (MMPI). Anticancer Research, 22(2A): 727-732, 2002. IF 1.4

51. G. Vitale, A. Ciccarelli, M. Caraglia, M. Galderisi, R. Rossi, S. Del Prete, A. Abbruzzese, G. Lupoli “Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole versus pentagastrin”
Clinical Chemistry, 48(9), 1505-1510, 2002 . IF 6.5

52. M. Caraglia, M. Marra, G. Giuberti, A.M. D’alessandro, S. Beninati, A. Lentini, S. Pepe, M. Boccellino And A. Abbruzzese “Theophylline- induced apoptosis is paralleled by Protein Kinase A-dependent tissue transglutaminase activation in cancer cells.”
Journal of Biochemistry, 132(1):45-52, 2002. IF 2.3

53. S. Del Prete, M. Caraglia, D. Russo, G. Vitale, G. Giuberti, M. Marra, A. M. D’Alessandro, G. Lupoli, R. Addeo, G. Facchini, R. Rossiello,

Curriculum Vitae Michele Caraglia

A. Abbruzzese, E. Capasso. “Percutaneous ethanol injection efficacy in the treatment of large symptomatic thyroid cystic nodules: ten-year follow-up on a large series.”
Thyroid, 12, 815-821, 2002. IF 2.4

54. M. Caraglia, P. Tagliaferri, M. Marra, G. Giuberti, A. Budillon, E. Di Gennaro, S. Pepe, G. Vitale, S. Improta, P. F. Tassone, S. Venuta, A. R. Bianco and A. Abbruzzese “EGF activates an inducible survival response via the RAS -> ERK-1/2 pathway to counteract interferon-α- mediated apoptosis in epidermoid cancer cells”.

Cell Death and Differentiation 10 (1), 218-229, 2003. IF 8.2

55. C. Esposito, M. Marra, G. Giuberti, A. M. D’Alessandro, R. Porta, A. Cozzolino, M. Caraglia*, A. Abbruzzese. Ubiquitination of tissue transglutaminase is modulated by interferon alpha in human lung cancer cells.

Biochemical Journal, 370, 205-212, 2003. IF 4.3 *CORRESPONDING AUTHOR

56. E. Di Gennaro, M. Barbarino, F. Bruzzese, S. De Lorenzo, M. Caraglia, A. Abbruzzese, S. Pepe, A. Avallone, G. Comella, F. Caponigro, and A. Budillon. Critical role of both p27KIP1and p21CIP1/WAF1 in the antiproliferative effect of ZD1839, an EGF receptor tyrosine kinase inhibitor in head and neck squamous carcinoma cells.
Journal of Cellular Physiology, 195, 139-150, 2003. IF 5.2

57. M. Caraglia , M. Marra, G. Giuberti, A.M. D’alessandro, P. Tassoni, S. Venuta, P. Tagliaferri, A. Abbruzzese “The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by Interferona and EGF in human cancer cells”

Journal of Biochemistry, 133, 757-765, 2003. IF 2.3

58. P. Tassone, P. Tagliaferri, C. Palmieri, C. Viscomi, E. Galea, M. Caraglia, A. M. D’Alessandro, A. Abbruzzese, A. Goel, C. R. Boland and S. Venuta “Zoledronic acid induces anti-proliferative activity and caspase-9-mediated apoptotic death of human pancreatic cancer cells” British Journal of Cancer, 88, 1971-1978, 2003. IF 3.8

59. M. Boccellino, G. Giuberti, L. Quagliuolo, M. Marra, L. Servillo, A. Abbruzzese and M. Caraglia. “Apoptosis induced by interferon-a is paralleled by caspase3-mediated cleavage of gelsolin in human epidermoid cancer cells”
Journal of Cellular Physiology, 201:71–83, 2004. IF 5.2

60. M. Caraglia, G. Vitale, M. Marra, S. Del Prete, A. Lentini, A. Budillon, S. Beninati, A. Abruzzese “Translational and Post-translational modifications of proteins as a new mechanism of action of Alpha-Interferon”
Amino Acids 26: 409–417, 2004. IF 2

61. A. Lamberti, M. Caraglia, O. Longo, M. Marra, A. Abbruzzese, P. Arcari “The translation elongation factor 1a in tumorigenesis, signal transduction and apoptosis”
Amino acids 26(4):443-8 2004. IF 2

62. A. Lentini, A. Abruzzese, M. Caraglia, M. Marra, S. Bennati “Protein-polyamine conjugation by transglutaminase in cancer cell differentiation: review artiche”.

Amino acids 26(4):331-337, 2004 IF 2

63. M. Caraglia*, G. Vitale, A. Colao, M. Marra, Alfredo Budillon, P. Tagliaferri and Alberto Abbruzzese “Alpha-Interferon And Its Effects On Signalling Pathways Within Cells”.

Current Protein Peptide Science 5(6):475-85, 2004. IF 3 *CORRESPONDING AUTHOR

64. M. Caraglia*, A.M. D’alessandro, M. Marra, G. Giuberti, G. Vitale, C. Viscomi, A Colao, S. Del Prete, P. Tagliaferri, P. Tassone, A. Budillon, S. Venuta and A. Abruzzese “The farnesyl transferase inhibitor R115777 (Zarnestra®) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa ®) and Pamidronate”.
Oncogene, 23(41):6900-13, 2004. IF 6.3

*CORRESPONDING AUTHOR

65. R. Addeo, M. Caraglia*, R. Costanzo, V. Faiola, L. Montella, A. Abbruzzese and S. Del Prete “Oxaliplatin/Rituximab combination in the treatment of intermediate-low grade NHL of elderly patients”
Oncology Reports, 12: 135-140, 2004 IF 1.4
*CORRESPONDING AUTHOR

Page 9 / 42

Curriculum Vitae Replace with First name(s) Surname(s)

66. E. Di Gennaro, F. Bruzzese, M. Caraglia, A. Abbruzzese, A. Budillon “Acetylation of proteins as novel target for antitumor therapy” Amino Acids 26(4):435-441, 2004 IF 2

67. P. Correale, S. Messinese, M. Caraglia, S. Marsili, A. Piccolomini, R. Petriol, F. Ceciarini, L. Micheli, C. Nencini, A. Neri, G. Vuolo, A. Guarnieri, A. Abbruzzese, S. Del Prete, G. Giorgi and G. Francini “A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5- fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma”
British Journal of Cancer, 90:1710-1714, 2004 IF 3.8

68. R. Addeo, F. Casale, M. Caraglia*, V. D’Angelo, S. Crisci, A. Abbruzzese, M.T. Di Tullio, P. Indolfi. “Glucocordicoids Induce G(1) Arrest of Lymphoblastic Cells Through Retinoblastoma Protein Rb1 Dephosphorylation in Childhood Acute Lymphoblastic Leukemia In Vivo.”

Cancer Biology & Therapy, 3(5):470-6. 2004 . IF 3.3 *CORRESPONDING AUTHOR

69. F. Mancinelli, M. Caraglia, A. Abbruzzese, G. D’ambrosio, R. Massa & E. Bismuto “non-thermal effects of electromagnetic fields at mobile phone frequency on the refolding of an intracellular protein: myoglobin.”
Journal of Cellular Biochemistry, 93(1):188-96, 2004. IF 3

70. F. Casale, V. D’Angelo, R. Addeo, M. Caraglia, S. Crisci, R. Rondelli, M.T. Di Tullio and P. Indolfi. “P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia.”
Oncology Reports, 12(6):1201-1208, 2004. IF 1.4

71. L. Montella, M. Caraglia*, A. Abbruzzese, A. Soricelli, S. Del Prete, G. Squame, M. Salvatore “Molecular technology and the recombinant TSH have changed the diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin.”
Experimental Molecular Medicine, 36(3):268-273, 2004. IF 1.7
* CORRESPONDING AUTHOR

72. G. Vitale, R. Pivonello, D. Ferone, MC De Martino, RS Auriemma, M.Caraglia, A. Abbruzzese, G. Lombardi, A. Colao The role of somatostatin receptors in the medical treatment of acromegaly.
Dig Liver Dis. 36 Suppl 1:S55-9, 2004. IF 1.4

73. P. Tagliaferri, M. Caraglia, A. Budillon, M. Marra, G. Vitale, C. Viscomi, S. Masciari, P. Tassone, A. Abbruzzese and S. Venuta “New pharmacokinetic and pharmacodynamic tools for Interferon a treatment of human cancer”.
Cancer Immunology Immunotherapy, 54(1):1-10 2005. IF 3.5

74. L. Montella, M. Caraglia*, R. Addeo, R. Costanzo, V. Faiola, A. Abbruzzese and S. Del Prete. Atrial fibrillation following chemotherapy for diffuse large B-cell-IIIE staged-gastric lymphoma in a patient with myotonic dystrophy (Steinert’s disease).
Annals of Haematology, 84(3):192-3, 2005. IF 1.3
*CORRESPONDING AUTHOR

75. M. Caraglia*, M. Marra, G. Pelaia, R. Maselli, M. Caputi, S. A. Marsico, A. Abbruzzese “Alpha-Interferon And Its Effects On Signal Transduction Pathways”

Journal of Cellular Physiology, 202(2):323-35, 2005. IF 5.2 *CORRESPONDING AUTHOR

76. G. Pelaia, G. Cuda, A. Vatrella, L. Gallelli, M. Caraglia, M. Marra, A. Abbruzzese, M. Caputi, R. Maselli, F. S. Costanzo, and S. A. Marsico “Mitogen-activated protein kinases and asthma”

Journal of Cellular Physiology, 202(3):642-653, 2005. IF 5.2

77. M. Caraglia*, Montella L, Addeo R, Costanzo R, Faiola V, Del Prete S, Baldi F, Baldi A, Abbruzzese A, Alloisio M. “Conditions suggesting lymphoma: case 2. Mediastinal liposarcoma in a patient with previous testicular cancer”.
Journal of Clinical Oncology, 23(16):3844-6, 2005. IF 9.8
*CORRESPONDING AUTHOR

78. L. Postiglione, G. Di Domenico, M. Caraglia*, M. Marra, G. Giuberti, L. del Vecchio, S. Montagnani, M. Macrì, E. M. Bruno, A. Abbruzzese, G. Rossi “Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: implications in the modulation of cell proliferation”
International Journal of Oncology, 26(5): 1193-1201, 2005 IF 3.1

*CORRESPONDING AUTHOR

Page 10 / 42

Curriculum Vitae Michele Caraglia

79. M. Caraglia*, A. Budillon, P. Tagliaferri, M. Marra, A. Abbruzzese, F. Caponigro.“Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications”
Current Drug Targets, 6(3):301-23, 2005. IF 4.1
* CORRESPONDING AUTHOR

80. P. Tagliaferri, P. Tassone, S. Blotta, C. Viscomi, F. Grillone, A. Budillon, M. Caraglia, and S. Venuta. “Antitumor Therapeutic Strategies Based On The Targeting Of Epidermal Growth Factor-Induced Survival Pathways”
Current Drug Targets, 6(3):289-300, 2005. IF 4.1

81. A. Budillon, F. Bruzzese, E. Di Gennaro, M. Caraglia “Multiple-targets drugs: inhibitors of Heat shock protein 90 and of Histone Deacetylase”
Current Drug Targets 6(3):337-51, 2005. IF 4.1

82. M. Caraglia*, G. Giuberti, M. Marra, E. Di Gennaro, G. Facchini, F. Caponigro, RV Iaffaioli, A. Budillon, A. Abruzzese “Docetaxel Induces p53-Dependent Apoptosis And Synergizes With Farnesyl Transferase Inhibitor R115777 In Human Epithelial Cancer Cells”
Frontiers in Bio-Science 10:2566-75, 2005. IF 3.2

*CORRESPONDING AUTHOR

83. F. Caponigro, R. Formato, M. Caraglia, N. Normanno, R. V. Iaffaioli “Monoclonal antibodies targeting EGFR and VEGF with a focus on head and neck tumors”
Current Opinion in Oncology, 17(3):212-217, 2005. IF 4

84. M. Caraglia*, M. Marra, F. Mancinelli, G. D’ambrosio, R. Massa, A. Giordano, A. Budillon, A. Abbruzzese & E. Bismuto “Electromagnetic fields at mobile phone frequency induce apoptosis and inactivation of the multi-chaperone complex in human epidermoid cancer cells”
Journal Of Cellular Physiology, 204(2):539-48, 2005. IF 5.2

*CORRESPONDING AUTHOR

85. R. Addeo, M. Caraglia*, A. Baldi, V. D’angelo, F. Casale, S.Crisci, A. Abbruzzese, B. Vincenzi, M. Campioni, M. T. Di Tullio, P. Indolfi, “Prognostic role of bcl-xl and p53 in Childhood Acute Lymphoblastic Leukemia (ALL)”
Cancer Biology & Therapy 4(1):32-8, 2005 IF 3.3
*CORRESPONDING AUTHOR

86. RV Iaffaioli, R Formato, A Tortoriello, S Del Prete, M Caraglia, G Pappagallo, A Pisano, F Fanelli, G Ianniello, S Cigolari, C Pizza, O Marano, G Pezzella, T Pedicini, A Febbraro, P Incoronato, L Manzione, E Ferrari, N Marzano, S Quattrin, S Pisconti, G Nasti, G Giotta, G Colucci. “Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer”.

British Journal of Cancer 92(9):1621-5, 2005. IF 3.8

87. P. Correale, F. Fulfaro, S. Marsili, G. Cicero, E. Bajardi, C. Intrivici, G. Vuolo, A. F. Carli, M. Caraglia, S. Del Prete, N. Gebbia, and G. Francini. Gemcitabine (GEM) plus oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.
Cancer Chemotherapy & Pharmacology 56(6):563-8, 2005. IF 2.2

88. L. Montella, M. Caraglia, A. Abbruzzese, A. Soricelli, M. Caputi, G. Squame, M. Salvatore, S. Del Prete, G. Calmieri “Mediastinal Images Resembling Thymus Following 131-I Treatment for Thyroid Cancer”
Monaldi Arch Chest Dis 63(2):114-7, 2005.

89. G. Facchini, F. Fiore., M. Caraglia*, R. D’Angelo, G. Nasti, F. Caponigro, R. Formato, A. Budillon, R. V. Iaffaioli
A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications.
Annals of Oncology 16(12):1980-1981, 2005. IF 4.4
*CORRESPONDING AUTHOR

90. Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete S, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, Formica V, Giorgi G, Bonmassar E, Francini G. “Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro.”

Journal of Immunology 175(2):820-828, 2005. IF 6.5

91. Caraglia M*, Marra M, Budillon A, Meo G, Ricciardiello F, Bismuto E, Brachelente G, Francini G, Giordano A, Correale P, Abbruzzese A. Chemotherapy Regimen GOLF Induces Apoptosis in Colon Cancer Cells through Multi-Chaperone Complex Inactivation and Increased Raf- 1 Ubiquitin-Dependent Degradation.
Cancer Biology & Therapy 4(10):1159-67, 2005. IF 3.2

*CORRESPONDING AUTHOR

Page 11 / 42

Curriculum Vitae Replace with First name(s) Surname(s)

92. Caraglia M*, Beninati S, Giuberti G, D’Alessandro AM, Lentini A, Abbruzzese A, Bove G, Landolfi F, Rossi F, Lampa E, Costantino M. Alternative therapy of earth elements increases the chondroprotective effects of chondroitin sulfate in mice.
Experimental Molecular Medicine 37(5):476-81, 2005. IF 1.7
*CORRESPONDING AUTHOR

93. M. Caraglia, M. Marra, G. Meo, S.R. Addeo, P. Tagliaferri and A. Budillon: EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.
Recent patents on Anti-Cancer Drug Discovery, 1(2):209-222, 2006.

94. D. Santini, G. Schiavon, S. Angeletti, B. Vincenzi, S. Gasparro, C. Grilli, A. La Cesa, V. Virzi, V. Leoni, A. Budillon, S. R. Addeo, M. Caraglia, G. Dicuonzo and G. Tonini “Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?”
Recent Patents on Anti-Cancer Drug Discovery, 1(3): 383-396, 2006.

95. M. Caraglia, M. Marra, C. Leonetti, G. Meo, S.R. Addeo, F. Bruzzese, P. Tagliaferri G. Zupi, A. Abbruzzese, A. Budillon: The farnesyl- transferase R115777 and the aminobisphosfonate zoledronic acid synergize on the apoptosis and on the growth inhibition of human cancers cells.
Haematologica reports 2(3):27-28, 2006.

96. Caraglia M., Dicitore A., Giuberti G., Cassese D., Lepretti M., Carteni M., Abbruzzese A., Stiuso P. Effects of VIP and VIP-DAP on proliferation and lipid peroxidation metabolism in human KB cells.
Ann N Y Acad Sci. 1070:167-72, 2006. IF 2

97. Caraglia M., Tassone P., Marra M., Budillon A., Venuta S., Tagliaferri P. Targeting Raf-kinase: molecular rationales and translational issues.
Ann Oncol. Jun;17(suppl.7):vii124-vii127, 2006. IF 4.4

98. Santini D., Caraglia M., Vincenzi B., Holen I., Scarpa S, Budillon A, Tonini G. Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates.
Nature Clinical Practice Oncology. 3(6):325-38, 2006.

99. Santini D, Graziano F, Catalano V, Di Seri M, Testa E, Baldelli AM, Giordani P, La Cesa A, Spalletta B, Vincenzi B, Russo A, Caraglia M, Virzi V, Cascinu S, Tonini G. Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial.
BMC Cancer. 6:125, 2006. IF 2

100. Mancinelli F, Caraglia M*, Budillon A, Abbruzzese A, Bismuto E. Molecular dynamics simulation and automated docking of the pro- apoptotic Bax protein and its complex with a peptide designed from the Bax-binding domain of anti-apoptotic Ku70.
Journal of Cellular Biochemistry. 1;99(1):305-18, 2006. IF 3.0
*CORRESPONDING AUTHOR

101. Caraglia M*, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates.
Endocrine-Related Cancer. 13(1):7-26, 2006. IF 4.6
*CORRESPONDING AUTHOR

102. Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A, Caraglia M*, Holen I. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
Oncology Reports. 5(5):1351-7, 2006. IF 1.4

*CORRESPONDING AUTHOR

103. Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Clinical Cancer Research 12(2):617-25, 2006. IF 5.7

104. P. Magistrelli, R. Coppola, G. Tonini, B. Vincenzi, D. Santini, D. Borzomati, F. Vecchio, S. Valeri, F. Castri, A. Antinori, G. Nuzzo, M. Caraglia* and A. Picciocchi. “Apoptotic Index or a combination of Bax/Bcl-2 expression correlates with survival after resection of pancreatic adenocarcinoma”
Journal of Cellular Biochemistry. 97(1):98-108, 2006. IF 3.0

*CORRESPONDING AUTHOR

105. Caraglia M*, Addeo R, Costanzo R, Montella L, Faiola V, Marra M, Abbruzzese A, Palmieri G, Budillon A, Grillone F, Venuta S, Tagliaferri P, Del Prete S. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.
Cancer Chemotherapy and Pharmacology. 57(1):34-9, 2006. IF 2.2

Page 12 / 42

Curriculum Vitae Michele Caraglia

*CORRESPONDING AUTHOR

106. Addeo R, Caraglia M, Faiola V, Capasso E, Vincenzi B, Montella L, Guarrasi R, Caserta L, Del Prete S. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life.
BMC Cancer. 25;7:18, 2007. IF 2

107. Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M*, Montella L. Cetuximab is an active treatment of metastatic and chemorefractory thymoma.
Frontiers in Bioscience. 12:757-61, 2007. IF 3.2
*CORRESPONDING AUTHOR

108. Santini D, Vincenzi B, Caraglia M, Tonini G. A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss.
Annals of Oncology. 18(1):201-2, 2007. IF 4.4

109. Ottaiano A, Facchini G, Nasti G, Budillon A, Caraglia M. * Phase II studies of anticancer chemotherapy: indirect evidence of poor quality.
Annals of Oncology. 18(2):403, 2007. IF 4.4
*CORRESPONDING AUTHOR

110. Naviglio S, Spina A, Marra M, Sorrentino A, Chiosi E, Romano M, Improta S, Budillon A, Illiano G, Abbruzzese A, Caraglia M* Adenylate cyclase/cAMP pathway downmodulation counteracts apoptosis induced by IFN-alpha in human epidermoid cancer cells.
Journal of Interferon and Cytokine Research. 27(2):129-36, 2007. IF 2.1
*CORRESPONDING AUTHOR

111. Palmieri G, Montella L, Aiello C, Barbieri F, Di Vizio D, Schulz S, Beninati S, Budillon A, Caraglia M*, Insabato L, Florio T. Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract.
Amino Acids. 2007 Feb 6. IF 2
*CORRESPONDING AUTHOR

112. Lentini A, Provenzano B, Caraglia M, Shevchenko A, Abbruzzese A, Beninati S. Impairment of the metastatic activity of melanoma cells by transglutaminase-catalyzed incorporation of polyamines into laminin and Matrigel.
Amino Acids. 2007 Mar 14. IF 2

113. Lamberti A, Longo O, Marra M, Tagliaferri P, Bismuto E, Fiengo A, Viscomi C, Budillon A, Rapp UR, Wang E, Venuta S, Abbruzzese A, Arcari P, Caraglia M*. C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A.
Cell Death and Differentiation. 14(5):952-62, 2007. IF 8.2

*CORRESPONDING AUTHOR

114. Lentini A, Mattioli P, Provenzano B, Abbruzzese A, Caraglia M, Beninati S. Role of the FAD-dependent polyamine oxidase in the selective formation of N(1),N(8)-bis(gamma- glutamyl)spermidine protein cross-links(1).
Biochemical Society Transactions. 35(2):396-400, 2007. IF 1.4

115. Caraglia M*, Marra M, Leonetti C, Meo G, D’Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A. R115777 (Zarnestra(R))/Zoledronic acid (Zometa(R)) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation.
Journal of Cellular Physiology. 211(2):533-43, 2007. IF 5.2

*CORRESPONDING AUTHOR

116. Addeo R, Crisci S, D’Angelo V, Vincenzi B, Casale F, Pettinato G, Donofrio V, Boldrini R, Alaggio R, Collini P, Bertorelle R, Di Tullio MT, Caraglia M*, Terenziani M, Lo Curto M, Indolfi P. Bax mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ cell tumors.
Oncology Reports. 17(5):1155-61, 2007. IF 1.4

*CORRESPONDING AUTHOR

117. Ottaiano A, Budillon A, Normanno N, Iaffaioli V, Caraglia M* A multidisciplinary approach is required to increase the quality of phase II/III clinical studies on biotherapies in oncology.
Annals of Oncology. 18(5):960-1, 2007. IF 4.4
*CORRESPONDING AUTHOR

118. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia M, Scarpa A, Palmieri M. Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
Biochemical and Biophysics Acta1773(7):1095-106, 2007 IF 4.4

Page 13 / 42

Curriculum Vitae Replace with First name(s) Surname(s)

119. Nasti G, Facchini G, Caraglia M*, Franco R, Mura AL, Staiano M, Budillon A, Iaffaioli RV, Ottaiano A. Concomitant occurrence of facial cutaneous and parotid gland metastases from rectal cancer after preoperative chemoradiotherapy.
Onkologie. 2007 Jun;30(6):324-6. 1.724 IF 1.724
*CORRESPONDING AUTHOR

120. Vetrano A, Addeo R, Russo I, Meo G, De Rosa G, D’Anna F, Caraglia M*. A case of clear renal cell cancer associated to meningioma and verrucous carcinoma of frontal region in an old patient.
J Exp Clin Cancer Res 26(1):157-9, 2007 IF 0.869
*CORRESPONDING AUTHOR

121. M. Marra, E. Agostinelli , G. Tempera, A. Lombardi, G. Meo, A. Budillon , G. Giuberti, A. Abbruzzese and M. Caraglia*. Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products.
Amino Acids 2007 Jul 4. IF 2
*CORRESPONDING AUTHOR

122. Avallone A, Di Gennaro E, Bruzzese F, Laus G, Delrio P, Caraglia M, Pepe S, Comella P, Budillon A. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Anticancer Drugs. 18(7):781-91, 2007.

123. A. Budillon, E. Di Gennaro, F. Bruzzese, M. Rocco, G. Manzo, M. Caraglia. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.
Recent patents on anti-cancer drug discovery 2(2):119-134, 2007

124. P. Tagliaferri, P. Tassone, A. Pietragalla, M.S. Rotundo, V. Barbieri, A. Budillon, M. Caraglia*, F.S. Costanzo, S. Venuta. Chemoprevention of BRCA1-related breast and ovarian tumours.
Recent patents on anti-cancer drug discovery 2(2):165-173, 2007
*CORRESPONDING AUTHOR

125. M. Sagristani, M. Caraglia*, M.R. Villa, A. Lucania, M. Esposito, L. Petriccione, S. Improta, M. Marra, G. Iannaci, R. Rossiello, L. Mastrullo. Concomitant occurrence of a primari renal NHL and of a papillary urothelial ureter cancer.
Journal of Experimental & Clinical Cancer Research. 26(2):291-2, 2007. IF 0.869
*CORRESPONDING AUTHOR

126. Facchini G, Caraglia M*, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Journal of Experimental & Clinical Cancer Research. 26(3):307-12, 2007. IF 0.869

*CORRESPONDING AUTHOR

127. Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, Cianfriglia M, Ciervo A, Caraglia M, Budillon A, Meo G, Arancia G, Molinari A. The Multidrug Transporter P-Glycoprotein: A Mediator of Melanoma Invasion?
Journal of Investigative Dermatology. 2007 Oct 18. IF 4.5

128. Addeo R, Faiola V, Guarrasi R, Montella L, Vincenzi B, Capasso E, Cennamo G, Rotundo MS, Tagliaferri P, Caraglia M, Del Prete S. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women >/=65 years of age.
Cancer Chemotherapy and Pharmacology. 2007 Oct 9. IF 2.363

129. Facchini G, Caraglia M*, Nasti G, Ottaiano A, Franco R, La Mura A, Fulciniti F, Libutti M, Ruberto M, Marra M, Budillon A, Iaffaioli R. Small tumor of the medial breast presenting with a contralateral lymph node involvement detected on positron emission tomography scan.

Annals of Oncology. 18(9):1579-80, 2007. IF 5.179 *CORRESPONDING AUTHOR

130. Addeo R, Nocera V, Faiola V, Vincenzi B, Ferraro G, Montella L, Guarrasi R, Rossi E, Cennamo G, Tonini G, Capasso E, Santini D, Caraglia M, Del Prete S. Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report.
Support Care Cancer. 2007 Aug 14. IF 1.905

131. Santini D, Vincenzi B, Galluzzo S, Battistoni F, Rocci L, Venditti O, Schiavon G, Angeletti S, Uzzalli F, Caraglia M, Dicuonzo G, Tonini G. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
Clinical Cancer Research. 13(15 Pt 1):4482-6, 2007. IF 6.177

132. Caraglia M*, Marra M, Viscomi C, D’Alessandro AM, Budillon A, Meo G, Arra C, Barbieri A, Rapp UR, Baldi A, Tassone P, Venuta S,

Curriculum Vitae Michele Caraglia

Abbruzzese A, Tagliaferri P. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferon- alpha through the inhibition of multiple survival pathways.
International Journal of Cancer. 121(10):2317-30, 2007. IF 4.693
*CORRESPONDING AUTHOR

133. Chiosi E, Spina A, Sorrentino A, Romano M, Sorvillo L, Senatore G, D’Auria R, Abbruzzese A, Caraglia M*, Naviglio S, Illiano G. Change in TNF-alpha receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death.
Journal of Interferon and Cytokine Research. 27(7):589-97, 2007. IF 2.472
*CORRESPONDING AUTHOR

134. Caraglia M*, Carteni M, Dicitore A, Cassese D, De Maria S, Ferranti P, Giuberti G, Abbruzzese A, Stiuso P. Experimental study on vasoactive intestinal peptide (VIP) and its diaminopropane bound (VIP-DAP) analog in solution.
Amino Acids. 2007 Jul 6. IF 2.104
*CORRESPONDING AUTHOR

135. Addeo R, Montella L, Baldi A, Cennamo G, Guarrasi R, Faiola V, Caraglia M, Del Prete S. Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma.
Clinical Colorectal Cancer. 6(10):728-30, 2007. IF 2.5

136. Caraglia M*, Marra M, Budillon A. Highlights of the annual meeting of the Italian Association for Cell Cultures (AICC): new drug delivery strategies and technological platforms for diagnosis and therapy of tumors (Part I) 6 – 7 December 2007, Naples, Italy.
Expert Opin Biol Ther.8(6):845-54, 2008 IF 2.7
*CORRESPONDING AUTHOR

137. Laezza C, Fiorentino L, Pisanti S, Gazzerro P, Caraglia M, Portella G, Vitale M, Bifulco M. Lovastatin induces apoptosis of k-ras- transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state.
J Mol Med. 86(12):1341-51, 2008. IF 5.192

138. Montella L, Addeo R, Caraglia M, Faiola V, Guarrasi R, Vincenzi B, Palmeri A, Capasso E, Nocera V, Tarantino L, Ariete M, Martorelli A, Del Prete S.Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
Oncol Rep. 20(2):385-90, 2008. IF 1.686

139. M. Marra, A. Lombardi, E. Agostinelli, G. Giuberti, S. Zappavigna, G. Tempera, G. Vitale, M. Bifulco, A. Abbruzzese, M. Caraglia*. Bovine serum amine oxidase and spermine potentiate docetaxel and interferon-a effects in inducing apoptosis on human cancer cells through the generation of oxidative stress.
BBA – Molecular Cell Research 1783(12):2269-78, 2008 IF 6.09

*CORRESPONDING AUTHOR

140. M. Marra, D. Santini, G. Tonini, G. Meo, S. Zappavigna, G. Facchini, A. Morabito, A. Abbruzzese, G. Cartenì, A. Budillon, M. Caraglia*. Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid
*CORRESPONDING AUTHOR
Europena Journal of Cancer suppl 6:79-85, 2008 IF 4.167

*CORRESPONDING AUTHOR

141. Addeo R, De Rosa C, Faiola V, Leo L, Cennamo G, Montella L, Guarrasi R, Vincenzi B, Caraglia M*, Del Prete S. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases.
Cancer 113(9):2524-31, 2008 IF 4.4

*CORRESPONDING AUTHOR

142. Vincenzi B, Patti G, Galluzzo S, Pantano F, Venditti O, Santini D, Ruzzo A, Schiavon G, Caraglia M, Marra M, Graziano F, Tonini G. Interleukin 1beta-511T gene (IL1beta) polymorphism is correlated with gastric cancer in the Caucasian population: results from a meta- analysis.
Oncol Rep. 20(5):1213-20, 2008 IF 1.4

143. Lepretti M, Costantini S, Ammirato G, Giuberti G, Caraglia M*, Facchiano AM, Metafora S, Stiuso P. The N-terminal 1-16 peptide derived in vivo from protein seminal vesicle protein IV modulates alpha-thrombin activity: potential clinical implications.
Exp Mol Med. 40(5):541-9, 2008 IF 1.7
*CORRESPONDING AUTHOR

144. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, Ventura M, Eramo PO, Viscomi C, Arbitrio M, Rossi M, Caraglia M, Munshi NC, Anderson KC, Tassone P. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
Br J Haematol. 143(4):520-31, 2008 IF 3.2

Page 15 / 42

Curriculum Vitae Replace with First name(s) Surname(s)

145. Vitale G, Caraglia M, van Koetsveld PM, Maroni P, Marra M, Colao A, Lamberts SW, Cavagnini F, Hofland LJ.Potential role of type I interferons in the treatment of pituitary adenomas.
Rev Endocr Metab Disord. 10(2):125-33, 2009 IF 1.9

146. M. Caraglia*, M. Marra, S.W.J. Lamberts, S. Zappavigna, G. Misso, F. Cavagnini, A. Abbruzzese, L.J. Hofland, G. Vitale. Emerging strategies to strengthen the anti-tumour activity of type I IFNs: overcoming survival pathways.
Current Cancer Drug Targets 9(5):690-704, 2009 IF 5.677
*CORRESPONDING AUTHOR

147. Naviglio S, Caraglia M*, Abbruzzese A, Chiosi E, Di Gesto D, Marra M, Romano M, Sorrentino A, Sorvillo L, Spina A, Illiano G. Protein kinase A as a biological target in cancer therapy.
Expert Opin Ther Targets. 13(1):83-92, 2009 IF 2.6
*CORRESPONDING AUTHOR

148. Vitale G, Gentilini D, Abbruzzese A, Caraglia M* Pyk2 and Cyr61 at the cross-road of cAMP-dependent signalling in invasiveness and neuroendocrine differentiation of prostate cancer.
Cancer Biol Ther. 8(3), 2009. IF 3.3
*CORRESPONDING AUTHOR

149. Correale P, Miano ST, Remondo C, Migali C, Rotundo MS, Macrì P, Tagliaferri P, Tassone P, Caraglia M, Gotti G, Francini G. Second- line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
Cancer Biol Ther. 8(6), 2009 IF 3.3

150. Addeo R, Caraglia M*, Del Prete S. Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. 7 November 2008, Naples, Italy. Expert Opin Investig Drugs. 18(3):373-8, 2009 IF 3.6
*CORRESPONDING AUTHOR

151. D’Angelo V, Crisci S, Casale F, Addeo R, Giuliano M, Pota E, Finsinger P, Baldi A, Rondelli R, Abbruzzese A, Caraglia M*, Indolfi P. High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases.
J Exp Clin Cancer Res. 19;28:39, 2009 IF 1.5
*CORRESPONDING AUTHOR

152. Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, Bulotta A, Neri P, Caraglia M*, Tagliaferri P. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo.
Cancer Biol Ther. 8(7):648-53, 2009 IF 3.3
*CORRESPONDING AUTHOR

153. Addeo R, Caraglia M*, Del Prete S Highlights of the Pananemia National meeting of the Italian Southern Oncological Group (GOIM): pharmacological and molecular treatment of cancer-induced anemia. Sorrento, Italy, 19-20 December 2008.
Expert Opin Pharmacother. 10(6):1089-93, 2009 IF 1.7
*CORRESPONDING AUTHOR

154. Fogli S, Caraglia M. Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives. Expert Opin Pharmacother 10(7):1095-108, 2009 IF 1.7

155. Montella L, Addeo R, Faiola V, Cennamo G, Guarrasi R, Capasso E, Mamone R, Caraglia M, Del Prete S. Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports.
J Exp Clin Cancer Res 13;28:7, 2009 IF 1.5

156. Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, Rosolowski M, Tonini G, Loeffler M, Lupu R, Abbruzzese A, Budillon A, Caraglia M*. CYR61 down-modulation potentiates the anticancer effects of zoledronic acid in androgen independent prostate cancer cells. International Journal of Cancer 125(9):2004-13, 2009 IF 4.7
*CORRESPONDING AUTHOR

157. Marra M, Giudice A, Arra C, Vitale G, Castiglioni S, Nasti G, Lombardi A, Ottaiano A, Facchini G, Iaffaioli RV, Abbruzzese A, Caraglia M*. Target-based agents in neo-adjuvant treatment of liver metastases from colo-rectal cancer: Secret weapons in anti-cancer war?
Cancer Biology and Therapy 8(18):1709-18, 2009 IF 2.761
*CORRESPONDING AUTHOR

158. Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, Tagliaferri P, Santini D, Caraglia M*. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects.
Current Cancer Drug Targets, 9(7):791-800, 2009 IF 4.187
*CORRESPONDING AUTHOR

Page 16 / 42

Curriculum Vitae Michele Caraglia

159. Naviglio S, Di Gesto D, Romano M, Sorrentino A, Illiano F, Sorvillo L, Abbruzzese A, Marra M, Caraglia M, Chiosi E, Spina A, Illiano G. Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells.
Cancer Biology and Therapy 8(12):1183-90, 2009. IF 2.761

160. Montella L, Addeo R, Palmieri G, Caraglia M, Cennamo G, Vincenzi B, Guarrasi R, Mamone R, Faiola V, Frega N, Capasso E, Maiorino L, Leopardo D, Pizza C, Montesarchio V, Del Prete S. Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series.
Cancer Chemother Pharmacol. Sep 16, 2009 IF 2.363

161. Facchini G, Perri F, Caraglia M, Pisano C, Striano S, Marra L, Fiore F, Aprea P, Pignata S, Iaffaioli RV. New treatment approaches in renal cell carcinoma.
Anticancer Drugs 20(10):893-900, 2009. IF 2.376

162. Addeo R, De Santi MS, Del Prete S, Caraglia M. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. Cancer Chemother Pharmacol. 64(5):863-6, 2009. IF 2.3

163. Montella L, Addeo R, Guarrasi R, Cennamo G, Faiola V, Capasso E, Caraglia M*, Prete SD. Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide.
Eur J Cancer Care (Engl). Jun 22, 2009 IF 1.138
*CORRESPONDING AUTHOR

164. Pantano F, Baldi A, Santini D, Vincenzi B, Borzomati D, Vecchio FM, Castri F, Antinori A, Caraglia M, Magistrelli P, Coppola R, Tonini G. MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients.
Cancer Biol Ther 8(11):996-9, 2009. IF 2.761

165. Sirangelo I, Iannuzzi C, Vilasi S, Irace G, Giuberti G, Misso G, D’Alessandro A, Abbruzzese A, Caraglia M*. W7FW14F apomyoglobin amyloid aggregates-mediated apoptosis is due to oxidative stress and AKT inactivation caused by Ras and Rac.
J Cell Physiol. 221(2):412-23, 2009. IF 5.2
*CORRESPONDING AUTHOR

166. Caraglia M*, Santini D. Target therapy of bone metastases and tumours.
Curr Cancer Drug Targets 9(7):789-90, 2009 IF 4.187 *CORRESPONDING AUTHOR

167. Santini D, Fratto ME, Vincenzi B, Napoli N, Galluzzo S, Tantardini M, Abbruzzese A, Caraglia M, Tonini G. Denosumab: the era of targeted therapies in bone metastatic diseases.
Curr Cancer Drug Targets 9(7):834-42, 2009. IF 4.187

168. Tassone P, Tagliaferri P, Rossi M, Calimeri T, Bulotta A, Abbruzzese A, Caraglia M, Neri P. Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy.
Curr Cancer Drug Targets 9(7):854-70, 2009 IF 4.187

169. Del Prete SD, Montella L, Caraglia M, Maiorino L, Cennamo G, Montesarchio V, Piai G, Febbraro A, Tarantino L, Capasso E, Palmieri G, Guarrasi R, Bianco M, Mamone R, Savastano C, Pisano A, Vincenzi B, Sabia A, D’Agostino A, Faiola V, Addeo R. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
Cancer Chemother Pharmacol 66(5):837-44. 2010 IF 2.3

170. Costantino M, Giuberti G, Caraglia M, Lombardi A, Misso G, Abbruzzese A, Ciani F, Lampa E. Possible antioxidant role of SPA therapy with chlorine-sulphur-bicarbonate mineral water.
Amino Acids 36:161–165 2009 IF 2.1

171. Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, Miragliuolo A, Guarrasi R, Lanna M, Cennamo G, Faiola V, Del Prete S. Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance.
J Clin Oncol. 28(4):543-8, 2010 IF 13.6

172. Caraglia M*, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Zoledronic acid: an unending tale for an anti-resorptive agent. Expert Opinion on Pharmacotherapy, 11(1):141-54, 2010 IF 2.077
*CORRESPONDING AUTHOR

173. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G. Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. Oncologist. 15(1):85-92, 2010. IF 6.63

174. Franco R, Cantile M, Scala S, Catalano E, Cerrone M, Scognamiglio G, Pinto A, Chiofalo MG, Caracò C, Anniciello AM, Abbruzzese A, Caraglia M*, Botti G. Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are

Curriculum Vitae Replace with First name(s) Surname(s)

correlated to clinical outcome.
Cancer Biology and Therapy 9(6):423-9. 2010 IF 2.761 *CORRESPONDING AUTHOR

175. Gazzerro P, Malfitano AM, Proto MC, Santoro A, Pisanti S, Caruso MG, Notarnicola M, Messa C, Laezza C, Misso G, Caraglia M, Bifulco M Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. Oncol Rep 23(1):171-5, 2010 IF 1.4

176. Stiuso P, Giuberti G, Lombardi A, Dicitore A, Limongelli V, Cartenì M, Abbruzzese A, Caraglia M*. gamma-Glutamyl 16- diaminopropane derivative of vasoactive intestinal peptide: a potent anti-oxidative agent for human epidermoid cancer cells.
Amino Acids. 39(3):661-70. 2010 IF 2
*CORRESPONDING AUTHOR

177. Giudice A, Caraglia M*, Marra M, Abbruzzese A, Arra C. Circadian rhythms and Haematopoiesis. Expert Opinion on Therapeutic Targets 14(5):567-75. 2010 IF 4.038 *CORRESPONDING AUTHOR

178. Correale P, Remando C, Migali C, Marra M, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tagliaferri P, Abbruzzese A, Arancini G, Caraglia M*. Cytotoxic drugs up-regulate Epidermal Growth Factor Receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted Antibody-Dependent-Cell-mediated-Cytotoxicity (ADCC).
European Journal of Cancer 46(9):1703-11. 2010 IF 4.475

*CORRESPONDING AUTHOR

179. Santini D, Vincenzi B, Adamo V, Addeo R, Fusco V, Russo A, Montemurro F, Roato I, Redana S, Lanzetta G, Satolli MA, Berruti A, Leoni V, Galluzzo S, Antimi M, Ferraro G, Rossi M, Del Prete S, Valerio MR, Marra M, Caraglia M, Tonini G. Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients.
Oncology Reports 25(6):1545-8. 2011 IF 1.4

180. Addeo R, Caraglia M, Cerbone D, Frega N, Cimmino G, Abbruzzese A, Del Prete S. Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer.
Expert Rev Anticancer Ther 10(4):499-505. 2010 IF 2.493

181. Santini D, Spoto C, Loupakis F, Vincenzi B, Silvestris N, Cremolini C, Canestrari E, Graziano F, Galluccio N, Salvatore L, Caraglia M, Zito FA, Colucci G, Falcone A, Tonini G, Ruzzo A. High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice.
Ann Oncol. 21(7):1565. 2010 IF 5.179

182. Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V, Baldi GG, Lai R, Rizzo S, Giacobino A, Chiusa L, Caraglia M, Russo A, Mackey J, Falcone A, Tonini G. Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC).
Curr Cancer Drug Targets.11(1):123-9. 2011 IF 4.187

183. Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rotonda MI, Leonetti C, Caraglia M, De Rosa G. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
Int J Pharm. 17;403(1-2):292-7. 2011 IF 2.962

184. Montella L, Addeo R, Caraglia M, Del Prete S. Latest developments in targeted therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 10(10):1635-46, 2010 IF 2.493

185. Vitale G, Fatti LM, Prolo S, Girola A, Caraglia M, Marra M, Abbruzzese A, Gerli G, Mari D. Screening for hypothyroidism in older hospitalized patients with anemia: a new insight into an old disease.
J Am Geriatr Soc. 58(9):1825-7, 2010. IF 3.656

186. Ostacolo L, Marra M, Ungaro F, Zappavigna S, Maglio G, Quaglia F, Abbruzzese A, Caraglia M. In vitro anticancer activity of docetaxel- loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role?
J Control Release. 148(2):255-63. 2010 IF 4.756

187. Pannone G, Bufo P, Santoro A, Franco R, Aquino G, Longo F, Botti G, Serpico R, Cafarelli B, Abbruzzese A, Caraglia M*, Papagerakis S, Lo Muzio L. WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors.
Oncol Rep.24(4):1035-41, 2010. IF 1.4
*CORRESPONDING AUTHOR

188. Addeo R, Sgambato A, Cennamo G, Montella L, Faiola V, Abbruzzese A, Capasso E, Leo L, Botti G, Caraglia M, Del Prete S. Low- dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer.
Clin Breast Cancer. 10(4):301-6, 2010. IF 2.427

Page 18 / 42

Curriculum Vitae Michele Caraglia

189. Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G. Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non- small-cell-lung cancer patients.

Cancer Biol Ther.9(9):685-93, 2010. IF 2.761

190. Addeo R, Caraglia M, De Santi MS, Montella L, Abbruzzese A, Parlato C, Vincenzi B, Carraturo M, Faiola V, Genovese M, Cennamo G, Del Prete S. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.
J Neurooncol. 102(3):417-24. 2011 IF 2.75

191. Campioni M, Severino A, Manente L, Tuduce IL, Toldo S, Caraglia M, Crispi S, Ehrmann M, He X, Maguire J, De Falco M, De Luca A, Shridhar V, Baldi A. The serine protease HtrA1 specifically interacts and degrades the tuberous sclerosis complex 2 protein.
Mol Cancer Res.8(9):1248-60, 2010. IF 4.16

192. Facchini G, Caraglia M*, Morabito A, Marra M, Piccirillo MC, Bochicchio AM, Striano S, Marra L, Nasti G, Ferrari E, Leopardo D, Vitale G, Gentilini D, Tortoriello A, Catalano A, Budillon A, Perrone F, Iaffaioli RV. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial.
Cancer Biol Ther. 10(6):543-548 2010. IF 2.761

*CORRESPONDING AUTHOR

193. Ungaro F, Conte C, Ostacolo L, Maglio G, Barbieri A, Arra C, Misso G, Abbruzzese A, Caraglia M, Quaglia F. Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: features, antiproliferative activity and in vivo toxicity. Nanomedicine. Sep 1. 8(5):637-46 2012 IF 6.202

194. Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Rotundo MS, Ciliberto D, Tomaino V, Fabiani F, Talarico D, Sperlongano P, Doldo P, Cannataro M, Caraglia M, Tassone P, Tagliaferri P. Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther. 12(9):780-7. 2011 IF 2.761

195. Grieco P, Franco R, Bozzuto G, Toccacieli L, Sgambato A, Marra M, Zappavigna S, Migaldi M, Rossi G, Striano S, Marra L, Gallo L, Cittadini A, Botti G, Novellino E, Molinari A, Budillon A and Caraglia M*. Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.
Journal of Cellular Biochemistry.112(1):341-53, 2011. IF 3.112

*CORRESPONDING AUTHOR

196. Faggiano A, Ramundo V, Dicitore A, Castiglioni S, Borghi MO, Severino R, Ferolla P, Crinò L, Abbruzzese A, Sperlongano P, Caraglia M, Ferone D, Hofland L, Colao A, Vitale G. Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.
J Cell Mol Med. 1582-4934 2011 IF 4.608

197. Perdonà S, Di Lorenzo G, Autorino R, Buonerba C, De Sio M, Setola SV, Fusco R, Ronza FM, Caraglia M, Ferro M, Petrillo A. Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. Urol Oncol. Sep 7. [Epub ahead of print] 2011 IF 3.17

198. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M, Caraglia M, Sperlongano P. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 9:171. Review. 2011 IF 3.51

199. Ferro M, Giuberti G, Zappavigna S, Perdonà S, Facchini G, Sperlongano P, Porto S, Di Lorenzo G, Buonerba C, Abbruzzese A, Altieri V, Caraglia M. Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. Oncol Rep. 27(2):409-15. 2012 IF 1.686

200. Caraglia M, Park MH, Wolff EC, Marra M, Abbruzzese A. eIF5A isoforms and cancer: two brothers for two functions? Amino Acids. Dec 3. [Epub ahead of print] 2011 IF 4.106

201. Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A, Accardo M, Tarantino L, Sordelli I, Agresti M, Abbruzzese A, Caraglia M, Palmieri G BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among

patients from South Italy. 19;3:e259. 2012

202.Caraglia M, Addeo R. Editorial: target therapy in brain tumours and metastases. 12(3):185. 2012 IF 4.771

Cell Death Dis. Curr Cancer Drug Targets.

Page 19 / 42

Curriculum Vitae Replace with First name(s) Surname(s)

203. Caraglia M, De Rosa G, Salzano G, Santini D, Lamberti M, Sperlongano P, Lombardi A, Abbruzzese A, Addeo R. Nanotech revolution for the anti-cancer drug delivery through blood- brain-barrier. Curr Cancer Drug Targets. 12(3):186-96. 2012 IF 4.771

204. Caraglia M, Marra M, Misso G, Lamberti M, Salzano G, De Rosa G, Abbruzzese A. Tumour-specific uptake of anti-cancer drugs: the future is here. Curr Drug Metab. 13(1):4-21. 2012 IF 3.896

205.De Rosa G, Salzano G, Caraglia M, Abbruzzese A. Nanotechnologies: a strategy to overcome blood-brain barrier. Curr Drug Metab. 13(1):61-9. 2012 IF 3.896

206. Sanges C, Scheuermann C, Zahedi RP, Sickmann A, Lamberti A, Migliaccio N, Baljuls A, Marra M, Zappavigna S, Rapp U, Abbruzzese A, Caraglia M, Arcari P. Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and

regulate its stability in eukaryotic cells. Death Dis. 1;3:e276. 2012

207. Galdiero M, Caraglia M. Curr Drug Metab. 13(1):2-3. 2012

Nanotechnological and

Cell

biotechnological strategies for drug delivery. IF 3.896

208.Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, Tassone P, Tagliaferri P. Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep. 27(6):1849-56. 2012 IF 1.686

209.Torricelli P, Caraglia M, Abbruzzese A, Beninati S. γ-Tocopherol inhibits human prostate cancer cell proliferation by up- regulation of transglutaminase 2 and down-regulation of cyclins. Amino Acids. Mar 30. [Epub ahead of print] 2012 IF 4.166

210. Misso G, Giuberti G, Lombardi A, Grimaldi A, Ricciardiello F, Giordano A, Tagliaferri P, Abbruzzese A, Caraglia M. Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC. J Cell Physiol. May 7. doi: 10.1002/jcp.24112. [Epub ahead of print] 2012 IF 3.986

211. Troiani T, Vecchione L, Martinelli E, Capasso A, Costantino S, Ciuffreda LP, Morgillo F, Vitagliano D, D’Aiuto E, De Palma R, Tejpar S, Van Cutsem E, De Lorenzi M, Caraglia M, Berrino L, Ciardiello F. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer. 106(10):1648-59. 2012 IF 4.346

212. Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese A, Sperlongano P, Misso G, Caraglia M, Tassone P, Tagliaferri P, Correale P. Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients. J Immunother. 35(5):440-7. 2012 IF 3.593

213.Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A, Misso G, Caraglia M. Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets Jun5 2012 IF 4.771

214.Addeo R, Caraglia M, Frega N, Del Prete S. Two faces for Janus: recombinant human erythropoiesis-stimulating agents and cancer mortality. Expert Rev Hematol. 2(5):513-5. 2009 IF 0.459

215. Franco R, Boscia F, Gigantino V, Marra L, Esposito F, Ferrara D, Pariante P, Botti G, Caraglia M, Minucci S, Chieffi P GPR30 is overexpressed in post-puberal testicular germ cell tumors. Cancer Biol Ther. 11(6):609-13. 2011 IF 2.907

216. Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, Ascani R, La Rotonda MI, Abbruzzese A, Tagliaferri P, Caraglia M, De Rosa G. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine. 7(6):955-64. 2011 IF 6.202

Curriculum Vitae Michele Caraglia

217. Santini D, Vincenzi B, Adamo V, Addeo R, Fusco V, Russo A, Montemurro F, Roato I, Redana S, Lanzetta G, Satolli MA, Berruti A, Leoni V, Galluzzo S, Antimi M, Ferraro G, Rossi M, Del Prete S, Valerio MR, Marra M, Caraglia M, Tonini G. Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. Oncol Rep. 25(6):1545-8. 2011 IF 1.686

218. Correale P, Botta C, Basile A, Pagliuchi M, Licchetta A, Martellucci I, Bestoso E, Apollinari S, Addeo R, Misso G, Romano O, Abbruzzese A, Lamberti M, Luzzi L, Gotti G, Rotundo MS, Caraglia M, Tagliaferri P. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol Ther. 12(2):112-8. 2011 IF 2.907

219. Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete SD, Abbruzzese A, Stiuso P Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2:e150. 2011

220. Donadelli M, Dando I, Zaniboni T, Costanzo C, Dalla Pozza E, Scupoli MT, Scarpa A, Zappavigna S, Marra M, Abbruzzese A, Bifulco M, Caraglia M, Palmieri M. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. Apr 28;2:e152. 2011

221. Addeo R, Caraglia M. Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera? Expert Opin Investig Drugs. 20(7):881-95. Review. 2011 IF 4.337

222. Correale P, Botta C, Cusi MG, Del Vecchio MT, De Santi MM, Gori Savellini G, Bestoso E, Apollinari S, Mannucci S, Marra M, Abbruzzese A, Aquino A, Turriziani M, Bonmassar L, Caraglia M, Tagliaferri P. Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer. 130(7):1577-89. 2012 IF 4.926

223. Bruzzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol. 226(9):2378-90. 2011
IF 3.986

224. Lamberti A, Sanges C, Chambery A, Migliaccio N, Rosso F, Di Maro A, Papale F, Marra M, Parente A, Caraglia M, Abbruzzese A, Arcari P. Analysis of interaction partners for eukaryotic translation elongation factor 1A M-domain by functional proteomics. Biochimie. 93(10):1738-46. Epub 2011 Jun 15. 2011 IF 3.728

225. Franco R, Caraglia M, Facchini G, Abbruzzese A, Botti G. The role of tissue microarray in the era of target-based agents. Expert Rev Anticancer Ther. 11(6):859-69. Review. 2011 IF 2.761

226. Di Domenico M, Santoro A, Ricciardi C, Iaccarino M, Iaccarino S, Freda M, Feola A, Sanguedolce F, Losito S, Pasquali D, Di Spiezio Sardo A, Bifulco G, Nappi C, Bufo P, Guida M, De Rosa G, Abbruzzese A, Caraglia M, Pannone G. Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. Cancer Biol Ther. 12(5):447-57. 2011 IF 2.907

227. Barbieri A, Palma G, Rosati A, Giudice A, Falco A, Petrillo A, Petrillo M, Bimonte S, Di Benedetto M, Esposito G, Stiuso P, Abbruzzese A, Caraglia M, Arra C. Role of endothelial nitric oxide synthase (eNOS) in chronic stress-promoted tumour growth. J Cell Mol Med. 16(4):920-6. 2012 IF 4.608

228. Marra M, Salzano G, Leonetti C, Porru M, Franco R, Zappavigna S, Liguori G, Botti G, Chieffi P, Lamberti M, Vitale G, Abbruzzese A, La Rotonda MI, De Rosa G, Caraglia M. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv. 30(1):302-9. 2012 IF 9.038

229. Caraglia M, Santini D, Bronte G, Rizzo S, Sortino G, Rini GB, Di Fede G, Russo A. Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules. Curr Drug Metab. 12(10):944-55. Review. 2011 IF 3,896

Curriculum Vitae Replace with First name(s) Surname(s)

230. Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M, Arancia G, Castiglioni S, Maroni P, Bendinelli P, Piccoletti R, van Koetsveld PM, Cavagnini F, Budillon A, Abbruzzese A, Hofland LJ, Caraglia M. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Biotechnol Adv. 30(1):169-84 2012. IF 9.038

231. Caraglia M, Addeo R “Editorial: target therapy in brain tumours and metastases.”
Curr Cancer Drug Targets. 12(3):185 2012. IF 4.327

232. Caraglia M*, Marra M, Misso G, Lamberti M, Salzano G, De Rosa G, Abbruzzese A. “Tumour-specific uptake of anti-cancer drugs: the future is here.”
Curr Drug Metab. Review.13(1):4-21.2012 IF 3.896
* CORRESPONDING AUTHOR

233. De Rosa G, Salzano G, Caraglia M, Abbruzzese A “Nanotechnologies: a strategy to overcome blood-brain barrier.” Curr Drug Metab Review. 13(1):61-9. 2012 IF 3.896

234. Sanges C, Scheuermann C, Zahedi RP, Sickmann A, Lamberti A, Migliaccio N, Baljuls A, Marra M, Zappavigna S, Reinders J, Rapp U, Abbruzzese A, Caraglia M, Arcari P. Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells.
Cell Death Dis.1;3:e276. 2012 doi: 10.1038/cddis.2012.16. IF. 5.333

235. Galdiero M, Caraglia M. Nanotechnological and biotechnological strategies for drug delivery. Curr Drug Metab. 13(1):2-32012 IF 3.896

236. Ciliberto D, Prati U, Roveda L, Barbieri V, Staropoli N, Abbruzzese A, Caraglia M, Di Maio M, Flotta D, Tassone P, Tagliaferri P Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials.
Oncol Rep.27(6):1849-56. 2012 IF 1.835

237. Troiani T, Vecchione L, Martinelli E, Capasso A, Costantino S, Ciuffreda LP, Morgillo F, Vitagliano D, D’Aiuto E, De Palma R, Tejpar S, Van Cutsem E, De Lorenzi M, Caraglia M, Berrino L, Ciardiello F. Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.
Br J Cancer. 8;106(10):1648-59. 2012 IF 5.042

238. Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese A, Sperlongano P, Misso G, Caraglia M, Tassone P, Tagliaferri P, Correale P. Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. J Immunother. 35(5):440-7. 2012 IF 3.267

239. Tassone P, Neri P, Burger R, Di Martino MT, Leone E, Amodio N, Caraglia M, Tagliaferri P. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.
Curr Cancer Drug Targets.12(7):814-22. 2012 IF 4.327

240. Lamberti M, Porto S, Marra M, Zappavigna S, Grimaldi A, Feola D, Pesce D, Naviglio S, Spina A, Sannolo N, Caraglia M* 5- Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress.

J Exp Clin Cancer Res. 19;31:60. 2012 IF 2.15 * CORRESPONDING AUTHOR

241. Aquino G, Pannone G, Santoro A, Liguori G, Franco R, Serpico R, Florio G, De Rosa A, Mattoni M, Cozza V, Botti G, Losito S, Longo F, Staibano S, Cuda G, Lo Muzio L, Sbordone C, Bufo P, Grimaldi A, Caraglia M*, Di Domenico M “pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: A tissue-microarray study with clinic-pathological correlations.”

Cancer Biol Ther 1;13(11):967-77. 2012 IF 2.636 * CORRESPONDING AUTHOR

242. Liguori G, Cantile M, Cerrone M, La Mantia E, Di Bonito M, Zanconati F, Curcio MP, Aquino G, La Mura A, Giannatiempo R, De Chiara A, Lombardi A, Botti G, D’Antonio A, Caraglia M, Franco R. “Breast MALT lymphomas: A clinicopathological and cytogenetic study of 9 cases.”
Oncol Rep. 28(4):1211-6. 2012 IF 1.835

243. Addeo R, Sperlongano P, Montella L, Vincenzi B, Carraturo M, Iodice P, Russo P, Parlato C, Salzano A, Cennamo G, Lombardi A, Sperlongano R, Prete SD, Caraglia M. “Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases.”
Cancer Chemother Pharmacol. 70(4):603-9.2012 IF 2.833

Page 22 / 42

Curriculum Vitae Michele Caraglia

244. Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, Tassone P, Tagliaferri P. “Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials.”
Eur J Cancer. 2012 Sep 15. pii: S0959-8049(12)00681-8. doi: 10.1016/j.ejca.2012.08.019. [Epub ahead of print]

IF 5.536

245. Misso G, Porru M, Stoppacciaro A, Castellano M, De Cicco F, Leonetti C, Santini D, Caraglia M* “Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid.”

Cancer Biol Ther. 2012 Sep 18;13(14). [Epub ahead of print] IF 2.636 * CORRESPONDING AUTHOR

246. Franco R, Nicoletti G, Lombardi A, Di Domenico M, Botti G, Zito Marino F, Caraglia M. “Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs.”
Expert Opin Biol Ther. 2012 Sep 24. [Epub ahead of print] IF 3.505

247. Caraglia M, Dicitore A, Marra M, Castiglioni S, Persani L, Sperlongano P, Tagliaferri P, Abbruzzese A, Vitale G. “Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties.”
Protein Pept Lett. 2012 Sep 13. [Epub ahead of print] IF 1.942

248. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Gallo Cantafio ME, Gullà A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P. “Synthetic miR-34a mimics as a novel therapeutic agent for Multiple Myeloma: in vitro and in vivo evidence.”
Clin Cancer Res. 2012 Oct 3. [Epub ahead of print] IF 7.742

249. Pelaia G, Gallelli L, Renda T, Fratto D, Falcone D, Caraglia M, Busceti MT, Terracciano R, Vatrella A, Maselli R, Savino R “Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells.”
Cell Prolif. 2012 Oct 10. doi: 10.1111/j.1365-2184.2012.00846.x. IF 2.521

250. Santini D, Addeo R, Vincenzi B, Calvieri A, Montella L, Silletta M, Caraglia M, Vespasiani U, Picardi A, Del Prete S, Tonini G. “Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.”
Expert Rev Anticancer Ther. 2012 Oct 24. IF 2.652

251. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D’Aquila P, Lionetti M, Fabiani F, Leone E, Gullà AM, Passarino G, Caraglia M, Negrini M, Neri A, Giordano A, Tagliaferri P, Tassone P. “DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget. 2012 Oct;3(10):1246-58. IF 4.784

252. Buonerba C, Caraglia M, Malgieri S, Perri F, Bosso D, Federico P, Ferro M, Rizzo M, Palmieri G, Di Lorenzo G Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?
Expert Opin Biol Ther. 2013 Feb;13(2):149-51. doi: 10.1517/14712598.2012.756470. Epub 2012 Dec 25. IF 3.505

253. Marra L, Cantile M, Scognamiglio G, Perdonà S, La Mantia E, Cerrone M, Gigantino V, Cillo C, Caraglia M, Pignata S, Facchini G, Botti G, Chieffi S, Chieffi P, Franco R Deregulation of HOX B13 expression in urinary bladder cancer progression. Curr Med Chem. 2013 Feb 1;20(6):833-9 IF 4.859

254. Troiani T, Zappavigna S, Martinelli E, Addeo SR, Stiuso P, Ciardiello F, Caraglia M. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.
Expert Opin Biol Ther. 2013 Feb;13(2):241-55. doi: 10.1517/14712598.2012.756469. IF 3.505

255. Perna AF, Sepe I, Lanza D, Capasso R, Zappavigna S, Capasso G, Caraglia M, Ingrosso D.
Hydrogen sulfide reduces cell adhesion and relevant inflammatory triggering by preventing ADAM17-dependent TNF-α activation. J Cell Biochem. 2013 Jan 7. doi: 10.1002/jcb.24495. [Epub ahead of print] IF 2.868

256. Caraglia M, Luongo L, Salzano G, Zappavigna S, Marra M, Guida F, Lusa S, Giordano C, De Novellis V, Rossi F, Abbruzzese Saccardi A, De Rosa G, Maione S. Stealth liposomes encapsulating zoledronic acid: a new opportunity to treat neuropathic pain.
Mol Pharm. 2013 Mar 4;10(3):1111-8. doi: 10.1021/mp3006215. IF 4.782

257. Spina A, Sorvillo L, Chiosi E, Esposito A, Di Maiolo F, Sapio L, Caraglia M, Naviglio S.
Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells. Oncol Rep. 2013 May;29(5):1689-96. doi: 10.3892/or.2013.2306. IF 1.835

258. Di Lorenzo G, Buonerba C, Gaudioso G, Gigantino V, Quarto G, De Domenico R, Caraglia M, Di Trolio R, Ascierto PA, De Placido S, Perdonà S, Franco R. EGFR mutational status in penile cancer.

Curriculum Vitae Replace with First name(s) Surname(s)

Expert Opin Ther Targets. 2013 May;17(5):501-5. doi: 10.1517/14728222.2013.783571. IF 3.505

259. Merlino F, Di Maro S, Munaim Yousif A, Caraglia M, Grieco P. Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures.
J Amino Acids. 2013;2013:979016. doi: 10.1155/2013/979016 IF 3.248

260. De Rosa G, Misso G, Salzano G, Caraglia M. Bisphosphonates and cancer: what opportunities from nanotechnology? J Drug Deliv. 2013;2013:637976. doi: 10.1155/2013/637976 IF 1.02

261. Addeo R, Zappavigna S, Luce A, Facchini S, Caraglia M.
Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. Expert Opin Drug Saf. 2013 Apr 8. [Epub ahead of print] IF 3.05

262. Franco R, Rocco G, Marino FZ, Pirozzi G, Normanno N, Morabito A, Sperlongano P, Stiuso P, Luce A, Botti G, Caraglia M. Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?
Expert Rev Anticancer Ther. 2013 Apr;13(4):407-20. doi: 10.1586/era.13.18. IF 2.652

263. Dicitore A, Caraglia M, Colao A, Zappavigna S, Mari D, Hofland LJ, Persani L, Vitale G.Combined Treatment With PPAR-γ Agonists In Pancreatic Cancer: A Glimmer Of Hope For Cancer Therapy?
Curr Cancer Drug Targets. 2013 Mar 25. [Epub ahead of print] IF. 4.327

264. Tesei A, Leonetti C, Di Donato M, Gabucci E, Porru M, Varchi G, Guerrini A, Amadori D, Arienti C, Pignatta S, Paganelli G, Caraglia M, Castoria G, Zoli W.
Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.

PLoS One. 2013 May 8;8(5):e62657. doi: 10.1371/journal.pone.0062657. IF 4.09

265. Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, Capone F, Leone A, Di Gennaro E, Caraglia M, Budillon A. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.

Cell Death Dis. 2013 May 23;4:e641. doi: 10.1038/cddis.2013.165. IF 6.044

266. Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, Capone F, Leone A, Di Gennaro E, Caraglia M, Budillon A Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.
Cell Death Dis. 2013 May 23;4:e641. doi: 10.1038/cddis.2013.16 IF 6.044

267. Gomez-Monterrey I, Campiglia P, Scognamiglio I, Vanacore D, Dicitore A, Lombardi A, Caraglia M, Novellino E, Stiuso P.
DTNQ-Pro, a Mimetic Dipeptide, Sensitizes Human Colon Cancer Cells to 5-Fluorouracil Treatment. J Amino Acids. 2013;2013:509056. doi: 10.1155/2013/509056. Epub 2013 Apr 21.

IF 3.914.

270. Misso G, Zappavigna S, Castellano M, De Rosa G, Di Martino MT, Tagliaferri P, Tassone P, Caraglia M Emerging pathways as individualized therapeutic target of multiple myeloma.
Expert Opin Biol Ther. 2013 Jun;13 Suppl 1:S95-109. doi: 10.1517/14712598.2013.807338. Epub 2013 Jun 6. IF 3.345

271. Pantano F, Guida FM, Vivaldi C, Vincenzi B, Grande E, Garrote MR, Caraglia M, Silvestris N, Vasile E, Masi G, Falcone A, Tonini G, Santini D.
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment.

Cancer Biol Ther. 2013 Jun;14(6):467-8. doi: 10.4161/cbt.24346. No abstract available. IF 3.287

272. Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P. Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.
Cancer Biol Ther. 2013 Jun;14(6):469-75. doi: 10.4161/cbt.24425. IF 3.287

268. De Rosa G, Caraglia M, Salmaso S, Elbayoumi T Nanotechnologies in cancer.
.J Drug Deliv. 2013;2013:604293. doi: 10.1155/2013/604293. Epub 2013 May 13. No abstract available.

269. Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N, Grimaldi A, Luce A, Tassone P, Caraglia M, Tagliaferri P. Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?
J Drug Deliv. 2013;2013:905091. doi: 10.1155/2013/905091. Epub 2013 May .

Page 24 / 42

Curriculum Vitae Michele Caraglia

273. Barbieri A, Barretta ML, Rea D, Picone C, Fabozzi O, Palma G, Antonio L, Federico A, Bimonte S, Setola F, De Lutio Di Castelguidone E, Castellano M, D’Errico AG, Caraglia M, Arra C. Intraluminal gel ultrasound and eco-color doppler: new tools for the study of colorectal cancer in mice.
In Vivo. 2013 Jul-Aug;27(4):443-50. IF 1.219

274. Falco A, Rosati A, Festa M, Basile A, De Marco M, d’Avenia M, Pascale M, Dal Piaz F, Tavano F, Di Mola FF, di Sebastiano P, Berloco PB, Nudo F, Caraglia M, Febbraro A, Barcaroli D, Scarpa A, Pezzilli R, De Laurenzi V, Turco MC BAG3 is a novel serum biomarker for pancreatic adenocarcinomas.
Am J Gastroenterol. 2013 Jul;108(7):1178-80. doi: 10.1038/ajg.2013.128. IF 7.553

.
275. Vitale G, Lupoli G, Guarrasi R, Colao A, Dicitore A, Gaudenzi G, Misso G, Castellano M, Addeo R, Facchini G, Del Prete S, Caraglia M Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies.
J Clin Endocrinol Metab. 2013 Oct;98(10):E1567-74. doi: 10.1210/jc.2013-1443IF 6.430.

276. Condello M, Caraglia M, Castellano M, Arancia G, Meschini S.
Structural and functional alterations of cellular components as revealed by electron microscopy. Microsc Res Tech. 2013 Oct;76(10):1057-69. doi: 10.1002/jemt.22266. IF 1.593

277. lannaccone M, Giuberti G, De Vivo G, Caraglia M, Gentile V Identification of a FXIIIA variant in human neuroblastoma cell lines. Int J Biochem Mol Biol. 2013 Jul 29;4(2):102-7. IF 4.152

278. Stiuso P, Caraglia M, De Rosa G, Giordano A. Bioactive peptides in cancer: therapeutic use and delivery strategies. J Amino Acids. 2013;2013:568953. doi: 10.1155/2013/568953 IF
3.914. .

279. Palma G, Barbieri A, Bimonte S, Palla M, Zappavigna S, Caraglia M, Ascierto PA, Ciliberto G, Arra C. Interleukin 18: Friend or foe in cancer.

Biochim Biophys Acta. 2013 Oct 8;1836(2):296-303. doi: 10.1016/j.bbcan.2013.09.001

280. Nicoletti R, Ferranti P, Caira S, Misso G, Castellano M, Di Lorenzo G, Caraglia M.
Myrtucommulone production by a strain of Neofusicoccum australe endophytic in myrtle (Myrtus communis). World J Microbiol Biotechnol. 2014 Mar;30(3):1047-52. doi:
IF 1.262

IF 3.848

10.1007/s11274-013-1523-x.

281. De Maria S, Scognamiglio I, Lombardi A, Amodio N, Caraglia M, Cartenì M, Ravagnan G, Stiuso P Polydatin, a natural precursor of resveratrol, induces cell cycle arrest and differentiation of human colorectal Caco2 cell.

J Transl Med. 2013 Oct 20;11(1):264. IF 3.46

282. Bruzzese F, Pucci B, Milone MR, Ciardiello C, Franco R, Chianese MI, Rocco M, Di Gennaro E, Leone A, Luciano A, Arra C, Santini D, Caraglia M, Budillon A. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Cell Death Dis. 2013 Oct 24;4:e878. doi: 10.1038/cddis.2013.406. IF 6.044

283. Grimaldi A, Balestrieri ML, D’Onofrio N, Di Domenico G, Nocera C, Lamberti M, Tonini G, Zoccoli A, Santini D, Caraglia M, Pantano F. The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrence.
PLoS One. 2013 Nov 11;8(11):e79658. doi: 10.1371/journal.pone.0079658. eCollection 2013.

284. Federico A, Zappavigna S, Romano M, Grieco P, Luce A, Marra M, Gravina AG, Stiuso P, D’Armiento FP, Vitale G, Tuccillo C, Novellino E, Loguercio C, Caraglia M. Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans. Eur J Clin Invest. 2013 Dec 30. doi: 10.1111/eci.12231.

285. Del Prete S, Cinieri S, Lorusso V, Maiorino L, Pizza C, Pisano A, Montesarchio V, Leo L, Savastano C, Pistolese G, Bianco M, Mabilia R, Tonachella R, Febbraro A, Manzione L, Palazzo S, Filippelli G, Vincenzi B, Barbato E, Cennamo G, Riccardi F, Misso G, Caraglia M, Addeo R. Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey.
Future Oncol. 2014 Jan;10(1):69-78. doi: 10.2217/fon.13.161.

286. Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P.
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.

Curriculum Vitae Replace with First name(s) Surname(s)

J Immunother. 2014 Jan;37(1):26-35. doi: 10.1097/CJI.0000000000000004.

287. Dicitore A, Caraglia M, Gaudenzi G, Manfredi G, Amato B, Mari D, Persani L, Arra C, Vitale G. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ): At the cross-road of pancreatic cancer cell proliferation.
Biochim Biophys Acta. 2014 Jan;1845(1):42-52. doi: 10.1016/j.bbcan.2013.11.003.

288. Pannone G, Santoro A, Feola A, Bufo P, Papagerakis P, Lo Muzio L, Staibano S, Ionna F, Longo F, Franco R, Aquino G, Contaldo M, De Maria S, Serpico R, De Rosa A, Rubini C, Papagerakis S, Giovane A, Tombolini V, Giordano A, Caraglia M, Di Domenico M.
The Role Of E-Cadherin Down-Regulation In Oral Cancer: Cdh1 Gene Expression And Epigenetic Blockage.
Curr Cancer Drug Targets. 2013 Nov 25. [Epub ahead of print]

289. D’Angelo V, Pecoraro G, Indolfi P, Iannotta A, Donofrio V, Errico ME, Indolfi C, Ramaglia M, Lombardi A, Di Martino M, Gigantino V, Baldi A, Caraglia M, De Luca A, Casale F. Expression and localization of serine protease Htra1 in neuroblastoma: correlation with cellular differentiation grade.
J Neurooncol. 2014 Apr;117(2):287-94. doi: 10.1007/s11060-014-1387-4. Epub 2014 Feb 4.

290. Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gullà A, Foresta U, Guzzi PH, Castellano M, Grimaldi A, Gigantino V, Franco R, Lusa S, Cannataro M, Tagliaferri P, De Rosa G, Tassone P, Caraglia M In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma.
PLoS One. 2014 Feb 27;9(2):e90005. doi: 10.1371/journal.pone.0090005. eCollection 2014.

291. Pizzi C, Arpino G, Acampora G, Aiello N, DE Rosa A, Diaferia I, DI Nunzio A, Fragna G, Franco A, Russo M, Sansone F, Scarpati C, Spinuso A, Arpino G, Luce A, Tommasielli G, Caraglia M, DE Placido S.
Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network.
Mol Clin Oncol. 2013 Jul;1(4):726-732. Epub 2013 Apr 4.

292. Marvaso G, Barone A, Amodio N, Raimondi L, Agosti V, Altomare E, Scotti V, Lombardi A, Bianco R, Bianco C, Caraglia M, Tassone P, Tagliaferri P.
Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro.
Cancer Biol Ther. 2014 Mar 21;15(6). [Epub ahead of print]

293. Staropoli N, Ciliberto D, Botta C, Fiorillo L, Grimaldi A, Lama S, Caraglia M, Salvino A, Tassone P, Tagliaferri P Pegylated liposomal doxorubicin in the management of ovarian cancer: A systematic review and metaanalysis of randomized trials.
.Cancer Biol Ther. 2014 Mar 21;15(6). [Epub ahead of print]

294. Scognamiglio I, Di Martino MT, Campani V, Virgilio A, Galeone A, Gullà A, Gallo Cantafio ME, Misso G, Tagliaferri P, Tassone P, Caraglia M, De Rosa G.
Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple Myeloma.
Biomed Res Int. 2014;2014:217365. doi: 10.1155/2014/217365. Epub 2014 Feb 13.

295. D’Onofrio N, Caraglia M, Grimaldi A, Marfella R, Servillo L, Paolisso G, Balestrieri ML.Vascular -homing peptides for targeted drug delivery and molecular imaging: Meeting the clinical challenges.
Biochim Biophys Acta. 2014 Apr 1;1846(1):1-12. doi: 10.1016/j.bbcan.2014.03.004. [Epub ahead of print] Review.

296. Lamberti M, Porto S, Zappavigna S, Addeo E, Marra M, Miraglia N, Sannolo N, Vanacore D, Stiuso P, Caraglia M. A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives. Toxicol Lett. 2014 Apr 1. pii: S0378-4274(14)00140-4. doi: 10.1016/j.toxlet.2014.03.018

297. Lamberti M, Zappavigna S, Sannolo N, Caraglia M.
Advantages and risks of nanotechnologies in cancer patients and occupationally exposed workers. Expert Opin Drug Deliv. 2014 Jul;11(7):1087-101. doi: 10.1517/17425247.2014.913568

298. Rossi M, Rotblat B, Ansell K, Amelio I, Caraglia M, Misso G, Bernassola F, Cavasotto CN, Knight RA, Ciechanover A, Melino G. High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy. Cell Death Dis. 2014 May 1;5:e1203. doi: 10.1038/cddis.2014.113.

299. Addeo R, Zappavigna S, Parlato C, Caraglia M Erlotinib: early clinical development in brain cancer. Expert Opin Investig Drugs. 2014 Jul;23(7):1027-37. doi10.1517/13543784.2014.918950..

300. Galdiero S, Falanga A, Vitiello M, Grieco P, Caraglia M, Morelli G, Galdiero M. Exploitation of viral properties for intracellular delivery.
J Pept Sci. 2014 Jul;20(7):468-78. doi: 10.1002/psc.2649.

301. Franco R, Zappavigna S, Gigantino V, Luce A, Cantile M, Cerrone M, Facchini G, Perdonà S, Pignata S, Di Lorenzo G, Chieffi S, Vitale G, De Sio M, Sgambato A, Botti G, Yousif AM, Novellino E, Grieco P, Caraglia M.
Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.

Curriculum Vitae

Michele Caraglia

J Exp Clin Cancer Res. 2014 Jun 3;33:48. doi: 10.1186/1756-9966-33-48.

302. Mesolella M, Luce A, Marino A, Caraglia M, Ricciardiello F, Iengo M. Treatment of c-kit positive adenoid cystic carcinoma of the tongue: A case report. Oncol Lett. 2014 Jul;8(1):309-312. Epub 2014 Apr 16.

303. Rizzo A, Misso G, Bevilacqua N, Donnarumma G, Lombardi A, Galdiero M, Caraglia M.
Zoledronic acid affects the cytotoxic effects of Chlamydia pneumoniae and the modulation of cytokine production in human osteosarcoma cells.
Int Immunopharmacol. 2014 Sep;22(1):66-72. doi: 10.1016/j.intimp.2014.06.019.

304. Stiuso P, Scognamiglio I, Murolo M, Ferranti P, De Simone C, Rizzo MR, Tuccillo C, Caraglia M, Loguercio C, Federico A. Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: a pilot study. Oxid Med Cell Longev. 2014:169216. doi: 10.1155/2014/169216.

305. Ieranò C, Santagata S, Napolitano M, Guardia F, Grimaldi A, Antignani E, Botti G, Consales C, Riccio A, Nanayakkara M, Barone MV, Caraglia M, Scala S.
CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.
Cell Death Dis. 2014 Jul 3;5:e1310. doi: 10.1038/cddis.2014.269.

306. Manfredi GI, Dicitore A, Gaudenzi G, Caraglia M, Persani L, Vitale G.
PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. Endocrine. 2014 Aug 13. [Epub ahead of print]

307. Monda M, Messina G, Scognamiglio I, Lombardi A, Martin GA, Sperlongano P, Porcelli M, Caraglia M, Stiuso P.
Short-term diet and moderate exercise in young overweight men modulate cardiocyte and hepatocarcinoma survival by oxidative stress. Oxid Med Cell Longev. 2014:131024. doi: 10.1155/2014/131024.

308. Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P, Tassone P, Caraglia M. Mir-34: a new weapon against cancer?
Mol Ther Nucleic Acids. 2014 Sep 23;3:e194. doi: 10.1038/mtna.2014.47. Review.

309. Caraglia M, Alaia C, Porcelli M. From Protein Synthesis to Molecular Biology: The Appealing Tale of eIF-5A. Mol Ther Nucleic Acids. 2014 Oct 7;3:e199. doi: 10.1038/mtna.2014.53. No abstract available

310. Vasca V, Vasca E, Freiman P, Marian D, Luce A, Mesolella M, Caraglia M, Ricciardiello F, Duminica T Keratin 5 expression in squamocellular carcinoma of the head and neck.
Oncol Lett. 2014 Dec;8(6):2501-2504. Epub 2014 Oct 9.

311. Porru M, Zappavigna S, Salzano G, Luce A, Stoppacciaro A, Balestrieri ML, Artuso S, Lusa S, De Rosa G, Leonetti C, Caraglia M. Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Oncotarget. 2014 Nov 15;5(21):10446-59.

312. Schiraldi C, Zappavigna S, D’ Agostino A, Porto S, Gaito O, Lusa S, Lamberti M, De Rosa M, De Rosa G, Caraglia M. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
Cancer Biol Ther. 2014;15(11):1524-32. doi: 10.4161/15384047.2014.955989.

313. Franco R, Collina F, Di Bonito M, Botti G, Montanaro D, Di Maio L, Vincenzi B, Landi G, D’Aiuto M, Caraglia M, Baldi A. HtrA1 loss is related to aggressive behavior parameters in sentinel node positive breast cancer.
Histol Histopathol. 2014 Dec 22.

314. Ilisso CP, Castellano M, Zappavigna S, Lombardi A, Vitale G, Dicitore A, Cacciapuoti G, Caraglia M, Porcelli M.
The methyl donor S-adenosylmethionine potentiates doxorubicin effects on apoptosis of hormone-dependent breast cancer cell lines. Endocrine. 2015 Jan 11.

315. De Rosa A, Zappavigna S, Villa MR, Improta S, Cesario E, Mastrullo L, Caraglia M, Stiuso P
Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab.
Oncol Lett. 2015 Mar;9(3):1327-1332. Epub 2014 Dec 19.

316. Lamberti M, Porto S, Zappavigna S, Stiuso P, Tirino V, Desiderio V, Mele L, Caraglia M.
Levofolene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: Clinical and occupational implications.

Curriculum Vitae Replace with First name(s) Surname(s)

Int J Oncol. 2015 Feb 24. doi: 10.3892/ijo.2015.2904.

317. Stiuso P, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, Addeo R, Prete SD, De Vita F, Russo A, Caraglia M.
MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib.

Mol Ther Nucleic Acids. 2015 Mar 17;4:e233. doi: 10.1038/mtna.2015.8.

318. Lamberti M, Pedata P, Sannolo N, Porto S, De Rosa A, Caraglia M.
Carbon nanotubes: Properties, biomedical applications, advantages and risks in patients and occupationally-exposed workers. Int J Immunopathol Pharmacol. 2015 Mar;28(1):4-13. doi: 10.1177/0394632015572559.

319. Dicitore A, Grassi ES, Caraglia M, Borghi MO, Gaudenzi G, Hofland LJ, Persani L, Vitale G.
The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines. Endocrine. 2016 Jan;51(1):101-12. doi: 10.1007/s12020-015-0597-7.

320. Grimaldi A, Santini D, Zappavigna S, Lombardi A, Misso G, Boccellino M, Desiderio V, Vitiello PP, Di Lorenzo G, Zoccoli A, Pantano F, Caraglia M. Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. Cancer Biol Ther. 2015;16(4):567-79. doi: 10.1080/15384047.2015.1018494. Epub 2015 Apr 11.

321. Pace MC, Passavanti MB, Aurilio C, Sansone P, Aurilio R, DE Maria S, Lama S, Federico A, Ravagnan G, Caraglia M, Stiuso P. Polydatin administration improves serum biochemical parameters and oxidative stress markers during chronic alcoholism: a pilot study. In Vivo. 2015 May-Jun;29(3):405-8.

322. Del Pup L, Mantovani A, Luce A, Cavaliere C, Facchini G, Di Francia R, Caraglia M, Berretta M. Endocrine disruptors and female cancer: Informing the patients (Review). Oncol Rep. 2015 Jul;34(1):3-11. doi: 10.3892/or.2015.3997. Epub 2015 May 20. Review.

323. Boccellino M, Alaia C, Misso G, Cossu AM, Facchini G, Piscitelli R, Quagliuolo L, Caraglia M Gene interference strategies as a new tool for the treatment of prostate cancer. Endocrine. 2015 Aug;49(3):588-605. doi: 10.1007/s12020-015-0629-3. Epub 2015 Jun 7.

324. Barbieri A, Bimonte S, Palma G, Luciano A, Rea D, Giudice A, Scognamiglio G, La Mantia E, Franco R, Perdonà S, De Cobelli O, Ferro M, Zappavigna S, Stiuso P, Caraglia M, Arra C. The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo. Int J Oncol. 2015 Aug;47(2):527-34. doi: 10.3892/ijo.2015.3038. Epub 2015 Jun 8.

325. Ciliberto D, Staropoli N, Caglioti F, Gualtieri S, Fiorillo L, Chiellino S, De Angelis AM, Mendicino F, Botta C, Caraglia M, Tassone P, Tagliaferri P. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? Cancer Biol Ther. 2015;16(8):1148-59. doi: 10.1080/15384047.2015.1056415. Epub 2015 Jun 10.

326. La Regina G, Bai R, Coluccia A, Famiglini V, Pelliccia S, Passacantilli S, Mazzoccoli C, Ruggieri V, Verrico A, Miele A, Monti L, Nalli M, Alfonsi R, Di Marcotullio L, Gulino A, Ricci B, Soriani A, Santoni A, Caraglia M, Porto S, Da Pozzo E, Martini C, Brancale A, Marinelli L, Novellino E, Vultaggio S, Varasi M, Mercurio C, Bigogno C, Dondio G, Hamel E, Lavia P, Silvestri R. New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog- Dependent Cancer. J Med Chem. 2015 Aug 13;58(15):5789-807. doi: 10.1021/acs.jmedchem.5b00310. Epub 2015 Jul 20.

327. Liguori G, Cantile M, Collina F, Marra L, DE Chiara A, Franco R, Caraglia M, Botti G, D’Andrea M, Nicoletti GF Atypical amplification of chromosome region 22q12 in melanoma: A case. report. Oncol Lett. 2015 Jul;10(1):349-353. Epub 2015 Apr 27.

328. Lamberti M, Capasso R, Lombardi A, Di Domenico M, Fiorelli A, Feola A, Perna AF, Santini M, Caraglia M, Ingrosso D. Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients. PLoS One. 2015 Aug 11;10(8):e0135331. doi: 10.1371/journal.pone.0135331. eCollection 2015.

329. D’Angelo V, Iannotta A, Ramaglia M, Lombardi A, Zarone MR, Desiderio V, Affinita MC, Pecoraro G, Di Martino M, Indolfi P, Casale

Curriculum Vitae Michele Caraglia

F, Caraglia M. EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches. J Exp Clin Cancer Res. 2015 Aug 14;34:83. doi: 10.1186/s13046-015-0191-0.

330. Pepe P, Castellano M, Alfano S, Della Pepa ME, Tirino V, Piemonte M, Desiderio V, Zappavigna S, Galdiero M, Caraglia M, Cringoli G, Rinaldi L, Galdiero M. Dicrocoelium dendriticum induces autophagic vacuoles accumulation in human hepatocarcinoma cells. Vet Parasitol. 2015 Sep 15;212(3-4):175-80. doi: 10.1016/j.vetpar.2015.07.039. Epub 2015 Aug 6.

331. Federico A, Dallio M, DI Fabio G, Zarrelli A, Zappavigna S, Stiuso P, Tuccillo C, Caraglia M, Loguercio C. Silybin-Phosphatidylcholine Complex Protects Human Gastric and Liver Cells from Oxidative Stress. In Vivo. 2015 Sep-Oct;29(5):569-75.

332. Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Giordano A, Desiderio V, Ghigo D, Caraglia M, De Rosa G, Riganti C Self- assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. Oncotarget. 2015 Oct 13;6(31):31461-78. doi: 10.18632/oncotarget.5058.

333. De Cobelli O, Buonerba C, Terracciano D, Bottero D, Lucarelli G, Bove P, Altieri V, Coman I, Perdonà S, Facchini G, Berretta M, Di Lorenzo G, Grieco P, Novellino E, Franco R, Caraglia M, Manini C, Mirone V, De Placido S, Sonpavde G, Ferro M. Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncol. 2015 Nov;11(22):3091-8. doi: 10.2217/fon.15.249. Epub 2015 Sep 18.

334. Ferro M, De Cobelli O, Buonerba C, Di Lorenzo G, Capece M, Bruzzese D, Autorino R, Bottero D, Cioffi A, Matei DV, Caraglia M et al. Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. Medicine (Baltimore). 2015 Oct;94(42):e1861. doi: 10.1097/MD.0000000000001861.

335. Perillo E, Porto S, Falanga A, Zappavigna S, Stiuso P, Tirino V, Desiderio V, Papaccio G, Galdiero M, Giordano A, Galdiero S, Caraglia M. Liposome armed with herpes virus-derived gH625 peptide to overcome doxorubicin resistance in lung adenocarcinoma cell lines. Oncotarget. 2016 Jan 26;7(4):4077-92. doi: 10.18632/oncotarget.6013.

336. Ricciardiello F, Fattore L, Liguori ME, Oliva F, Luce A, Abate T, Caraglia M, Pianese A, Raucci AF. Temporal bone meningioma involving the middle ear: A case report.
Oncol Lett. 2015 Oct;10(4):2249-2252. Epub 2015 Jul 20.

337. Klionsky DJ et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016 Jan 2;12(1):1-222. No abstract available.

338. Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Pinzòn-Daza ML, Giordano A, Desiderio V, Ghigo D, De Rosa G, Caraglia M, Riganti C. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. Oncotarget. 2016 Mar 9. doi: 10.18632/oncotarget.8012.

339. Ieranò C, Portella L, Lusa S, Salzano G, D’Alterio C, Napolitano M, Buoncervello M, Macchia D, Spada M, Barbieri A, Luciano A, Barone MV, Gabriele L, Caraglia M, Arra C, De Rosa G, Scala S. CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. Nanoscale. 2016 Mar 31;8(14):7562-71. doi: 10.1039/c5nr06335c.

340. Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, Tassone P. Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016 Mar 28. pii: molcanther.0985.2015.

341. Berretta M, Caraglia M, Martellotta F, Zappavigna S, Lombardi A, Fierro C, Atripaldi L, Muto T, Valente D, De Paoli P, Tirelli U, Di Francia R. Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV Infection. Front Pharmacol. 2016 Mar 30;7:71. doi: 10.3389/fphar.2016.00071. eCollection 2016. Review.

Curriculum Vitae Replace with First name(s) Surname(s)

342. Mesolella M, Iorio B, Misso G, Luce A, Cimmino M, Iengo M, Landi M, Sperlongano P,Caraglia M, Ricciardiello F Role of perineural invasion as a prognostic factor in laryngeal cancer. Oncol Lett. 2016 Apr;11(4):2595-2598. Epub 2016 Feb 24.

343. Zappavigna S, Misso G, Falanga A, Perillo E, Novellino E, Galdiero M, Grieco P, Caraglia M, Galdiero S. Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses. Curr Pharm Biotechnol. 2016 Apr 15

344. Stiuso P, Bagarolo ML, Ilisso CP, Vanacore D, Martino E, Caraglia M, Porcelli M, Cacciapuoti G.
Protective Effect of Tyrosol and S-Adenosylmethionine against Ethanol-Induced Oxidative Stress of Hepg2 Cells Involves Sirtuin 1, P53 and Erk1/2 Signaling. Int J Mol Sci. 2016 Apr 26;17(5). pii: E622. doi: 10.3390/ijms17050622.

345. Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, Tassone P. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Mol Cancer Ther. 2016 Jun;15(6):1364-75. doi: 10.1158/1535-7163.MCT-15-0985-T.

346. Misso G, Zarone MR, Grimaldi A, Di Martino MT, Lombardi A, Kawasaki H, Stiuso P, Tassone P, Tagliaferri P, Caraglia M. Non Coding RNAs: a new avenue for the self-tailoring of blood cancer treatment. Curr Drug Targets. 2017;18(1):35-55.

347. Salzano G, Zappavigna S, Luce A, D’Onofrio N, Balestrieri ML, Grimaldi A, Lusa S, Ingrosso D, Artuso S, Porru M, Leonetti C, Caraglia M, De Rosa G. Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth. J Biomed Nanotechnol. 2016 Apr;12(4):811-30.

348. Federico A, Zappavigna S, Dallio M, Misso G, Merlino F, Loguercio C, Novellino E, Grieco P, Caraglia M. Urotensin-II receptor: a double identity receptor involved in vasoconstriction and in the development of digestive tract cancers and other tumors. Curr Cancer Drug Targets. 2017;17(2):109-121.

349. Del Pup L, Mantovani A, Cavaliere C, Facchini G, Luce A, Sperlongano P, Caraglia M, Berretta M. Carcinogenetic mechanisms of endocrine disruptors in female cancers (Review). Oncol Rep. 2016 Aug;36(2):603-12. doi: 10.3892/or.2016.4886.

350. Addeo R, Caraglia M, Iuliano G. Pembrolizumab: the value of PDL1 biomarker in head and neck cancer. Expert Opin Biol Ther. 2016 Sep;16(9):1075-8. doi: 10.1080/14712598.2016.1211635.

351. Botta C, Misso G, Martino EC, Pirtoli L, Cusi MG, Tassone P, Tagliaferri P, Caraglia M, Correale P. The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response. Cell Death Dis. 2016 Jul 21;7:e2299. doi: 10.1038/cddis.2016.211.

352. Di Lorenzo G, De Placido S, Pagliuca M, Ferro M, Lucarelli G, Rossetti S, Bosso D, Puglia L, Pignataro P, Ascione I, De Cobelli O, Caraglia M, Aieta M, Terracciano D, Facchini G, Buonerba C, Sonpavde G. The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. Expert Opin Biol Ther. 2016 Nov;16(11):1387-1401.

353. Ramaglia M, D’Angelo V, Iannotta A, Di Pinto D, Pota E, Affinita MC, Donofrio V, Errico ME, Lombardi A, Indolfi C, Casale F, Caraglia M. High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas. Cancer Cell Int. 2016 Jul 28;16:59. doi: 0.1186/s12935-016-0338-x.

354. Gagliardi A, Carbone C, Russo A, Cuccurullo R, Lucania A, Cioppa PD, Misso G, Caraglia M, Tommasino C, Mastrullo L. Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports. Oncol Lett. 2016 Oct;12(4):2363-2370.

355. Boccellino M, Quagliuolo L, Alaia C, Grimaldi A, Addeo R, Nicoletti GF, Kast RE, Caraglia M. The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity. Curr Med Res Opin. 2016 Nov;32(11):1839-1848.

356. Martino EC, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C, Botta C, Capone F, Lombardi A, Pirtoli L, Tassone P, Ulivieri C, Tagliaferri P, Cusi MG, Caraglia M, Correale P. Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. Cell Death Discov. 2016 Oct 3;2:16025.

357. Carbone C, Di Gennaro E, Piro G, Milone MR, Pucci B, Caraglia M, Budillon A. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat. Amino Acids. 2016 Oct 19.

358. Zappavigna S, Scuotto M, Cossu AM, Ingrosso D, De Rosa M, Schiraldi C, Filosa R, Caraglia M. The 1,4 benzoquinone-featured 5- lipoxygenase inhibitor RF-Id induces apoptotic death through downregulation of IAPs in human glioblastoma cells. J Exp Clin Cancer Res. 2016 Oct 22;35(1):167.

359. Romano FJ, Rossetti S, Conteduca V, Schepisi G, Cavaliere C, Di Franco R, La Mantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Quagliariello V, Piscitelli R, Pepe MF, Berretta M, D’Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, De Giorgi U, Facchini G. Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. Oncotarget. 2016 Dec 20;7(51):85641-85649. doi: 10.18632/oncotarget.13063. IF 5.5

Curriculum Vitae Michele Caraglia

360. Simental-Mendía LE, Caraglia M, Majeed M, Sahebkar A. Impact of curcumin on the regulation of microRNAs in colorectal cancer. Expert Rev Gastroenterol Hepatol. 2017 Feb;11(2):99-101. doi: 10.1080/17474124.2017.1268528. IF 2.8

361. Potenza N, Mosca N, Zappavigna S, Castiello F, Panella M, Ferri C, Vanacore D, Giordano A, Stiuso P, Caraglia M, Russo A. MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells. J Cell Physiol. 2017 Jul;232(7):1907-1913. IF 4.15

362. Cave DD, Desiderio V, Mosca L, Paola Ilisso C, Mele L, Caraglia M, Cacciapuoti G, Porcelli M. S-ADENOSYLMETHIONINE-MEDIATED APOPTOSIS IS POTENTIATED BY AUTOPHAGY INHIBITION INDUCED BY CHLOROQUINE IN HUMAN BREAST CANCER CELLS.
J Cell Physiol. 2017 May 18. doi: 10.1002/jcp.26015. [Epub ahead of print]

363. Correale P, Botta C, Ciliberto D, Pastina P, Ingargiola R, Zappavigna S, Tassone P, Pirtoli L, Caraglia M, Tagliaferri P. Immunotherapy of colorectal cancer: new perspectives after a long path.
Immunotherapy. 2016 Nov;8(11):1281-1292.

364. Berretta M, Di Francia R, De Diviitis C, Nasti G, Canzonieri V, Caraglia M, Facchini G, Tirelli U.
The Role of Target Therapy in the Treatment of Gastrointestinal Non Colorectal Cancers: Clinical Impact and Cost Consideration. Curr Cancer Drug Targets. 2017 Feb 8. doi: 10.2174/1568009617666170208162058.

365. Facchini G, Perri F, Misso G, D Aniello C, Scarpati GD, Rossetti S, Pepa CD, Pisconti S, Unteregger G, Cossu A, Caraglia M, Berretta M, Cavaliere C.
Optimal Management of Prostate Cancer Based on its Natural Clinical History.
Curr Cancer Drug Targets. 2017 Feb 8. doi: 10.2174/1568009617666170209093101.

366. D Aniello C, Perri F, Scarpati GD, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C.
MELANOMA ADJUVANT TREATMENT: current insight and clinical features.
Curr Cancer Drug Targets. 2017 Feb 8. doi: 10.2174/1568009617666170208163714.

367. Zappavigna S, Lombardi A, Misso G, Grimaldi A, Caraglia M. Measurement of Autophagy by Flow Cytometry.
Methods Mol Biol. 2017;1553:209-216.

368. Dicitore A, Grassi ES, Borghi MO, Gelmini G, Cantone MC, Gaudenzi G, Persani L, Caraglia M, Vitale G. Antitumor activity of interferon-β1a in hormone refractory prostate cancer with neuroendocrine differentiation. J Endocrinol Invest. 2017 Jul;40(7):761-770.

369. Shahabipour F, Caraglia M, Majeed M, Derosa G, Maffioli P, Sahebkar A. Naturally occurring anti-cancer agents targeting EZH2.
Cancer Lett. 2017 Aug 1;400:325-335.

370. Irace C, Misso G, Capuozzo A, Piccolo M, Riccardi C, Luchini A, Caraglia M, Paduano L, Montesarchio D, Santamaria R. Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.
Sci Rep. 2017 Mar 28;7:45236.

371. Quagliariello V, Rossetti S, Cavaliere C, Di Palo R, Lamantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Romano FJ, Piscitelli R, Iovane G, Pepe MF, Berretta M, D’Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, Iaffaioli RV, Facchini G.
Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.

Oncotarget. 2017 May 2;8(18):30606-30616. doi: 10.18632/oncotarget.16725.

372. Lombardi A, Grimaldi A, Zappavigna S, Misso G, Caraglia M.
Hepatocarcinoma: genetic and epigenetic features.
Minerva Gastroenterol Dietol. 2017 Apr 11. doi: 10.23736/S1121-421X.17.02408-4. [Epub ahead of print]

373. Vanacore D, Boccellino M, Rossetti S, Cavaliere C, D’Aniello C, Di Franco R, Romano FJ, Montanari M, La Mantia E, Piscitelli R, Nocerino F, Cappuccio F, Grimaldi G, Izzo A, Castaldo L, Pepe MF, Malzone MG, Iovane G, Ametrano G, Stiuso P, Quagliuolo L, Barberio D, Perdonà S, Muto P, Montella M, Maiolino P, Veneziani BM, Botti G, Caraglia M, Facchini G. Micrornas in prostate cancer: an overview. Oncotarget. 2017 Jul 25;8(30):50240-50251.

374. Vitale G, Dicitore A, Pepe D, Gentilini D, Grassi ES, Borghi MO, Gelmini G, Cantone MC, Gaudenzi G, Misso G, Di Blasio AM, Hofland LJ, Caraglia M, Persani L.

Curriculum Vitae Replace with First name(s) Surname(s)

Synergistic activity of everolimus and 5-aza-2′-deoxycytidine in medullary thyroid carcinoma cell lines. Mol Oncol. 2017 Apr 28. doi: 10.1002/1878-0261.12070.

375. Lo Re O, Panebianco C, Porto S, Cervi C, Rappa F, Di Biase S, Caraglia M, Pazienza V, Vinciguerra M.
Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells. J Cell Physiol. 2017 May 4. doi: 10.1002/jcp.25987.

376. Borghese C, Casagrande N, Pivetta E, Colombatti A, Boccellino M, Amler E, Normanno N, Caraglia M, De Rosa G, Aldinucci D. Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells. Oncotarget. 2017 Jun 27;8(26):42926-42938.

377. Momtazi-Borojeni AA, Abdollahi E, Ghasemi F, Caraglia M, Sahebkar A.
The novel role of pyrvinium in cancer therapy.
J Cell Physiol. 2017 May 13. doi: 10.1002/jcp.26006. [Epub ahead of print] Review. PMID: 28500633

378. Saberi-Karimian M, Katsiki N, Caraglia M, Boccellino M, Majeed M, Sahebkar A.
Vascular endothelial growth factor: an important molecular target of curcumin.
Crit Rev Food Sci Nutr. 2017 Aug 30:0. doi: 10.1080/10408398.2017.1366892. [Epub ahead of print]

379. Ottaiano A, Nasti G, Cassata A, De Stefano A, Caraglia M, Avallone A. FOLFOXIRI in metastatic colorectal cancer: a criticism from its native land. Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30512-8. doi: 10.1016/j.canlet.2017.08.025. [Epub ahead of print]

380. Grimaldi A, Zarone MR, Irace C, Zappavigna S, Lombardi A, Kawasaki H, Caraglia M, Misso G.
Non-coding RNAs as a new dawn in tumor diagnosis. Semin Cell Dev Biol. 2017 Jul 29. pii: S1084-9521(17)30258-6. doi: 10.1016/j.semcdb.2017.07.035. [Epub ahead of print]

381. Kawasaki H, Lombardi A, Caraglia M Determination of miRNAs from Cancer Stem Cells Using a Low Density Array Platform. .Methods Mol Biol. 2018;1692:149-156. doi: 10.1007/978-1-4939-7401-6_14.

382. Hamzehzadeh L, Caraglia M, Atkin SL, Sahebkar A. Dickkopf homolog 3 (DKK3): A candidate for detection and treatment of cancers? J Cell Physiol. 2018 Jun;233(6):4595-4605. doi: 10.1002/jcp.26313. Epub 2018 Jan 15. Review.

383. Alaia C, Boccellino M, Zappavigna S, Amler E, Quagliuolo L, Rossetti S, Facchini G, Caraglia M.
Ipilimumab for the treatment of metastatic prostate cancer. Expert Opin Biol Ther. 2018 Feb;18(2):205-213. doi: 10.1080/14712598.2018.1420777. Epub 2017 Dec 28. Review.

384. Ristori S, Grillo I, Lusa S, Thamm J, Valentino G, Campani V,CaragliaM, Steiniger F, Luciani P, De Rosa G. Structural Characterization of Self-Assembling Hybrid Nanoparticles for Bisphosphonate Delivery in Tumors. Mol Pharm. 2018 Mar 5;15(3):1258-1265. doi: 10.1021/acs.molpharmaceut.7b01085. Epub 2018 Feb 20.

385. Di Martino MT, Zazzeroni F, Donadelli M, Chiodoni C, Caraglia M, Scotlandi K, Meschini S, Leonetti C.
Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy. J Exp Clin Cancer Res. 2018 Mar 5;37(1):48. doi: 10.1186/s13046-018-0710-x. No abstract available.

386. Hosseinpour-Moghaddam K, Caraglia M, Sahebkar A. Autophagy induction by trehalose: Molecular mechanisms and therapeutic impacts. J Cell Physiol. 2018 Sep;233(9):6524-6543. doi: 10.1002/jcp.26583. Epub 2018 Apr 16. Review.

387. Grassia V, Lombardi A, Kawasaki H, Ferri C, Perillo L, Mosca L, Delle Cave D, Nucci L, Porcelli M, Caraglia M.Salivary microRNAs as new molecular markers in cleft lip and palate: a new frontier in molecular medicine. Oncotarget. 2018 Apr 10;9(27):18929-18938. doi: 10.18632/oncotarget.24838. eCollection 2018 Apr 10.

388. Correale P, Botta C, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, Giannicola R, Fioravanti A, Giordano A, Zappavigna S, Caraglia M, Tassone P, Pirtoli L, Cusi MG, Tagliaferri PSystemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.
Oncotarget. 2018 Apr 17;9(29):20539-20554. doi: 10.18632/oncotarget.24993. eCollection 2018 Apr 17

389. Mele L, Paino F, Papaccio F, Regad T, Boocock D, Stiuso P, Lombardi A, Liccardo D, Aquino G, Barbieri A, Arra C, Coveney C, La Noce M, Papaccio G, Caraglia M, Tirino V, Desiderio V. A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo. Cell Death Dis. 2018 May 1;9(5):572. doi: 10.1038/s41419-018- 0635-5.

Curriculum Vitae Michele Caraglia

390. Ottaiano A, De Stefano A, Capozzi M, Nappi A, De Divitiis C, Romano C, Silvestro L, Cassata A, Casaretti R, Tafuto S, Caraglia M, Berretta M, Nasti G, Avallone A. First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis.
Front Pharmacol. 2018 May 3;9:441. doi: 10.3389/fphar.2018.00441. eCollection 2018. Review.

391. Momtazi-Borojeni AA, Ghasemi F, Hesari A, Majeed M,CaragliaM, Sahebkar A. Anti-Cancer and Radio-Sensitizing Effects of Curcumin in Nasopharyngeal Carcinoma. Curr Pharm Des. 2018;24(19):2121-2128. doi: 10.2174/1381612824666180522105202.

392. Scognamiglio P, Chiaradia G, Giovanetti M, Albertini E, Camposeragna A, Farinella M, Lorenzetti D, Oldrini M, Rancilio L, Caraglia A, Maraglino FP, Ippolito G, Girardi E. HIV rapid testing in community and outreach sites: results of a nationwide demonstration project in Italy. BMC Public Health. 2018 Jun 18;18(1):748. doi: 10.1186/s12889-018-5680-6.

393. Tatulli F, Delcuratolo A, Caraglia A, Notarnicola A, Carbone FPN, Caputi A. Three-trocar laparoscopic cholecystectomy under spinal anesthesia in a patient with asthma. G Chir. 2018 May-Jun;39(3):188-190.

394. Martano M, Stiuso P, Facchiano A, De Maria S, Vanacore D, Restucci B, Rubini C, Caraglia M, Ravagnan G, Lo Muzio L. Aryl hydrocarbon receptor, a tumor grade-associated marker of oral cancer, is directly downregulated by polydatin: A pilot study. Oncol Rep. 2018 Sep;40(3):1435-1442. doi: 10.3892/or.2018.6555. Epub 2018 Jul 10.

395. Orditura M, Della Corte CM, Diana A, Ciaramella V, Franzese E, Famiglietti V, Panarese I, Franco R, Grimaldi A, Lombardi A, Caraglia M, Santoriello A, Procaccini E, Lieto E, Maiello E, De Vita F, Ciardiello F, Morgillo FThree dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs. Breast. 2018 Oct;41:165-171. doi: 10.1016/j.breast.2018.08.002. Epub 2018 Aug 4.

396. Ricciardiello F, Addeo R, Di Lullo AM, Abate T, Mazzone S, Oliva F, Motta G, Caraglia M, Mesolella M. Adenoid cystic carcinoma of the larynx in a 70-year-old patient: A case report. Oncol Lett. 2018 Sep;16(3):2783-2788. doi: 10.3892/ol.2018.8976. Epub 2018 Jun 18.

397. D’Arena G, Seneca E, Migliaccio I, De Feo V, Giudice A, La Rocca F, Capunzo M, Calapai G, Festa A, Caraglia M, Musto P, Iorio EL, Ruggieri V. Oxidative stress in chronic lymphocytic leukemia: still a matter of debate. Leuk Lymphoma. 2018 Sep 20:1-9. doi: 10.1080/10428194.2018.1509317.

398. Giarra S, Zappavigna S, Campani V, Abate M, Cossu AM, Leonetti C, Porru M, Mayol L, Caraglia M, De Rosa G. Chitosan-Based Polyelectrolyte Complexes for Doxorubicin and Zoledronic Acid Combined Therapy to Overcome Multidrug Resistance. Pharmaceutics. 2018 Oct 9;10(4). pii: E180. doi: 10.3390/pharmaceutics10040180.

399. Cordani M, Butera G, Dando I, Torrens-Mas M, Butturini E, Pacchiana R, Oppici E, Cavallini C, Gasperini S, Tamassia N, Nadal- Serrano M, Coan M, Rossi D, Gaidano G, Caraglia M, Mariotto S, Spizzo R, Roca P, Oliver J, Scupoli MT, Donadelli M. Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O2-· production in cancer cells. Br J Cancer. 2018 Oct;119(8):994-1008. doi: 10.1038/s41416-018-0288-2. Epub 2018 Oct 15.

400. Ilisso CP, Delle Cave D, Mosca L, Pagano M, Coppola A, Mele L, Caraglia M, Cacciapuoti G, Porcelli M S Adenosylmethionine regulates apoptosis and autophagy in MCF-7 breast cancer cells through the modulation of specific microRNAs. Cancer Cell Int. 2018 Dec 4;18:197. doi: 10.1186/s12935-018-0697-6. eCollection 2018.

401. Quagliariello V, Masarone M, Armenia E, Giudice A, Barbarisi M, Caraglia M, Barbarisi A, Persico M. Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells. Oncol Rep. 2019 Mar;41(3):1476-1486. doi: 10.3892/or.2018.6932. Epub 2018 Dec 13. PMID: 30569138; PMCID: PMC6365699. 536.

402. Mosca L, Pagano M, Ilisso CP, Cave DD, Desiderio V, Mele L, Caraglia M, Cacciapuoti G, Porcelli M. AdoMet triggers apoptosis in head and neck squamous cancer by inducing ER stress and potentiates cell sensitivity to cisplatin. J Cell Physiol. 2019 Aug;234(8):13277- 13291. doi: 10.1002/jcp.28000. Epub 2018 Dec 21. PMID: 30575033.

403. Panarese I, Aquino G, Ronchi A, Longo F, Montella M, Cozzolino I, Roccuzzo G, Colella G, Caraglia M, Franco R. Oral and Oropharyngeal squam

404. Addeo R, Ghiani M, Merlino F, Ricciardiello F, Caraglia M. CheckMate 141
trial: all that glitters is not gold. Expert Opin Biol Ther. 2019
Mar;19(3):169-171. doi: 10.1080/14712598.2019.1570498. Epub 2019 Jan 21. PMID: 30652499.

404. Nigro E, Stiuso P, Matera MG, Monaco ML, Caraglia M, Maniscalco M, Perrotta

Page 33 / 42

Curriculum Vitae

Replace with First name(s) Surname(s)

F, Mazzarella G, Daniele A, Bianco A. The anti-proliferative effects of
adiponectin on human lung adenocarcinoma A549%cells and oxidative stress involvement. Pulm Pharmacol Ther. 2019 Apr;55:25-30. doi:
10.1016/j.pupt.2019.01.004. Epub 2019 Jan 15. PMID: 30654148.
405. Condello M, Pellegrini E, Caraglia M, Meschini S. Targeting Autophagy to Overcome Human Diseases. Int J Mol Sci. 2019 Feb 8;20(3):725. doi: 10.3390/ijms20030725. PMID: 30744021; PMCID: PMC6387456.
406. Chiodoni C, Di Martino MT, Zazzeroni F, Caraglia M, Donadelli M, Meschini S, Leonetti C, Scotlandi K. Cell communication and signaling: how to turn bad
language into positive one. J Exp Clin Cancer Res. 2019 Mar 13;38(1):128. doi: 10.1186/s13046-019-1122-2. Erratum in: J Exp Clin Cancer Res. 2019 Oct
25;38(1):425. PMID: 30867009; PMCID: PMC6417210.
407. Mele L, la Noce M, Paino F, Regad T, Wagner S, Liccardo D, Papaccio G, Lombardi A, Caraglia M, Tirino V, Desiderio V, Papaccio F. Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast
cancer cells through autophagy perturbation. J Exp Clin Cancer Res. 2019 Apr 12;38(1):160. doi: 10.1186/s13046-019-1164-5. PMID: 30987650; PMCID: PMC6466760

408. Misso G, Zarone MR, Lombardi A, Grimaldi A, Cossu AM, Ferri C, Russo M, Vuoso DC, Luce A, Kawasaki H, Di Martino MT, Virgilio A, Festa A, Galeone A, De Rosa G, Irace C, Donadelli M, Necas A, Amler E, Tagliaferri P, Tassone P,
Caraglia M. miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma. Mol Ther Nucleic Acids. 2019 Jun 7;16:391-406. doi: 10.1016/j.omtn.2019.02.023. Epub 2019 Mar 13. PMID: 31009917; PMCID: PMC6479071.

409. Zappavigna S, Vanacore D, Lama S, Potenza N, Russo A, Ferranti P, Dallio M, Federico A, Loguercio C, Sperlongano P, Caraglia M, Stiuso P. Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells. Int J Mol Sci. 2019 May 3;20(9):2190. doi: 10.3390/ijms20092190. PMID: 31058823; PMCID: PMC6539179.

410. Piccolo M, Misso G, Ferraro MG, Riccardi C, Capuozzo A, Zarone MR, Maione F, Trifuoggi M, Stiuso P, D’Errico G, Caraglia M, Paduano L, Montesarchio D, Irace
C, Santamaria R. Exploring cellular uptake, accumulation and mechanism of action
of a cationic Ru-based nanosystem in human preclinical models of breast cancer.

Page 34 / 42

Curriculum Vitae

Michele Caraglia

Sci Rep. 2019 May 7;9(1):7006. doi: 10.1038/s41598-019-43411-3. PMID: 31065032; PMCID: PMC6505035.
411. Al-Juboori SI, Vadakekolathu J, Idri S, Wagner S, Zafeiris D, Pearson JR, Almshayakhchi R, Caraglia M, Desiderio V, Miles AK, Boocock DJ, Ball GR, Regad T. PYK2 promotes HER2-positive breast cancer invasion. J Exp Clin Cancer Res. 2019 May 22;38(1):210. doi: 10.1186/s13046-019-1221-0. PMID: 31118051; PMCID: PMC6532260.

412. Abate M, Festa A, Falco M, Lombardi A, Luce A, Grimaldi A, Zappavigna S, Sperlongano P, Irace C, Caraglia M, Misso G. Mitochondria as playmakers of apoptosis, autophagy and senescence. Semin Cell Dev Biol. 2020 Feb;98:139-153. doi: 10.1016/j.semcdb.2019.05.022. Epub 2019 Jun 27. PMID: 31154010.

413. Della Corte CM, Barra G, Ciaramella V, Di Liello R, Vicidomini G, Zappavigna S, Luce A, Abate M, Fiorelli A, Caraglia M, Santini M, Martinelli E, Troiani T, Ciardiello F, Morgillo F. Antitumor activity of dual blockade of PD-L1 and MEK
in NSCLC patients derived three-dimensional spheroid cultures. J Exp Clin Cancer Res. 2019 Jun 13;38(1):253. doi: 10.1186/s13046-019-1257-1. PMID: 31196138; PMCID: PMC6567578.

414. Addeo R, Caraglia M, Vincenzi B, Luce A, Montella L, Mastella A, Mazzone S, Ricciardiello F, Carraturo M, Del Prete S, Sperlongano P. Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study. Chemotherapy. 2019;64(1):48-56. doi: 10.1159/000500714. Epub 2019 Jun 26. PMID: 31242489. 415. Addeo R, Lamberti G, Simonetti G, Iodice P, Marinelli A, Montella L, Cappabianca S, Gaviani P, Caraglia M, Prete SD, Silvani A. Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity

assessment of a multicenter study. CNS Oncol. 2019 Jun 1;8(2):CNS32. doi: 10.2217/cns-2019-0004. Epub 2019 Jul 10. PMID: 31290692; PMCID: PMC6713024. 416. Gravina AG, Dallio M, Tuccillo C, Martorano M, Abenavoli L, Luzza F, Stiuso
P, Lama S, Grieco P, Merlino F, Caraglia M, Loguercio C, Federico A. Urotensin
II receptor expression in patients with ulcerative colitis: a pilot study.
Minerva Gastroenterol Dietol. 2020 Mar;66(1):23-28. doi: 10.23736/S1121-421X.19.02602-3. Epub 2019 Jul 9. PMID: 31293119.

Page 35 / 42

Curriculum Vitae

Replace with First name(s) Surname(s)

417. Cossu AM, Mosca L, Zappavigna S, Misso G, Bocchetti M, De Micco F, Quagliuolo L, Porcelli M, Caraglia M, Boccellino M. Long Non-coding RNAs as Important Biomarkers in Laryngeal Cancer and Other Head and Neck Tumours. Int J Mol Sci. 2019 Jul 12;20(14):3444. doi: 10.3390/ijms20143444. PMID: 31336999; PMCID: PMC6678449.

418. Giudice A, Barbieri A, Bimonte S, Cascella M, Cuomo A, Crispo A, D’Arena G, Galdiero M, Della Pepa ME, Botti G, Caraglia M, Capunzo M, Arra C, Montella M. Dissecting the prevention of estrogen-dependent breast carcinogenesis through Nrf2-dependent and independent mechanisms. Onco Targets Ther. 2019 Jun 24;12:4937-4953. doi: 10.2147/OTT.S183192. PMID: 31388303; PMCID: PMC6607693. 419. Zappavigna S, Cossu AM, Abate M, Misso G, Lombardi A, Caraglia M, Filosa R.

A Hydroquinone-Based Derivative Elicits Apoptosis and Autophagy via Activating a ROS-Dependent Unfolded Protein Response in Human Glioblastoma. Int J Mol Sci. 2019 Aug 6;20(15):3836. doi: 10.3390/ijms20153836. PMID: 31390836; PMCID: PMC6696486.

420. Capasso A, Benigni A, Capitanio U, Danesh FR, Di Marzo V, Gesualdo L, Grandaliano G, Jaimes EA, Malyszko J, Perazella MA, Qian Q, Ronco P, Rosner MH, Trepiccione F, Viggiano D, Zoccali C, Capasso G; International Conference on Onco-Nephrology Participants. Summary of the International Conference on Onco- Nephrology: an emerging field in medicine. Kidney Int. 2019 Sep;96(3):555-567.
doi: 10.1016/j.kint.2019.04.043. Epub 2019 May 31. PMID: 31445584.
421. Del Prete S, Caraglia M, Luce A, Montella L, Galizia G, Sperlongano P, Cennamo G, Lieto E, Capasso E, Fiorentino O, Aliberti M, Auricchio A, Iodice P, Addeo R. Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience. Oncol Lett. 2019 Oct;18(4):3873-3879. doi: 10.3892/ol.2019.10729. Epub 2019 Aug 7. PMID: 31516598; PMCID: PMC6732960.
422. Vitiello PP, De Falco V, Giunta EF, Ciardiello D, Cardone C, Vitale P,
Zanaletti N, Borrelli C, Poliero L, Terminiello M, Arrichiello G, Caputo V,
Famiglietti V, Mattera Iacono V, Marrone F, Di Liello A, Martini G, Napolitano
S, Caraglia M, Lombardi A, Franco R, De Vita F, Morgillo F, Troiani T,
Ciardiello F, Martinelli E. Clinical Practice Use of Liquid Biopsy to Identify
RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A

Page 36 / 42

Curriculum Vitae

Michele Caraglia

Single Institution Experience. Cancers (Basel). 2019 Oct 8;11(10):1504. doi: 10.3390/cancers11101504. PMID: 31597339; PMCID: PMC6827157.
423. Chiodoni C, Di Martino MT, Zazzeroni F, Caraglia M, Donadelli M, Meschini S, Leonetti C, Scotlandi K. Correction to: Cell communication and signaling: how to
turn bad language into positive one. J Exp Clin Cancer Res. 2019 Oct
25;38(1):425. doi: 10.1186/s13046-019-1431-5. Erratum for: J Exp Clin Cancer
Res. 2019 Mar 13;38(1):128. PMID: 31651343; PMCID: PMC6814022.
424. Stasio DD, Mosca L, Lucchese A, Cave DD, Kawasaki H, Lombardi A, Porcelli M, Caraglia M. Salivary mir-27b Expression in Oral Lichen Planus Patients: A Series
of Cases and a Narrative Review of Literature. Curr Top Med Chem. 2019;19(31):2816-2823. doi: 10.2174/1568026619666191121144407. PMID: 31755392. 425. Caraglia M, Correale P, Giannicola R, Staropoli N, Botta C, Pastina P, Nesci
A, Caporlingua N, Francini E, Ridolfi L, Mini E, Roviello G, Ciliberto D,
Agostino RM, Strangio A, Azzarello D, Nardone V, Falzea A, Cappabianca S,
Bocchetti M, D’Arrigo G, Tripepi G, Tassone P, Addeo R, Giordano A, Pirtoli L,
Francini G, Tagliaferri P. GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. Front Oncol.
2019 Nov 8;9:1102. doi: 10.3389/fonc.2019.01102. PMID: 31781481; PMCID: PMC6857002.
426. Franzese E, Centonze S, Diana A, Lombardi A, Carlino F, Guerrera LP, De Vita
F, Caraglia M, Pignata S, Ciardiello F, Orditura M. Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. Front Oncol. 2019 Nov 29;9:1289.
doi: 10.3389/fonc.2019.01289. PMID: 31850198; PMCID: PMC6895028.
427. Correale P, Saladino RE, Nardone V, Giannicola R, Agostino R, Pirtoli L,
Caraglia M, Botta C, Tagliaferri P. Could PD-1/PDL1 immune checkpoints be linked
to HLA signature? Immunotherapy. 2019 Dec;11(18):1523-1526. doi: 10.2217/imt-2019-0160. Epub 2019 Dec 9. PMID: 31865873.
428. Zappavigna S, Abate M, Cossu AM, Lusa S, Campani V, Scotti L, Luce A, Yousif AM, Merlino F, Grieco P, De Rosa G, Caraglia M. Urotensin-II-Targeted Liposomes
as a New Drug Delivery System towards Prostate and Colon Cancer Cells. J Oncol. 2019 Dec 17;2019:9293560. doi: 10.1155/2019/9293560. PMID: 31929800; PMCID: PMC6942863.

Page 37 / 42

Curriculum Vitae

Replace with First name(s) Surname(s)

429. Nardone V, Tini P, Pastina P, Botta C, Reginelli A, Carbone SF, Giannicola
R, Calabrese G, Tebala C, Guida C, Giudice A, Barbieri V, Tassone P, Tagliaferri
P, Cappabianca S, Capasso R, Luce A, Caraglia M, Mazzei MA, Pirtoli L, Correale
P. Radiomics predicts survival of patients with advanced non-small cell lung
cancer undergoing PD-1 blockade using Nivolumab. Oncol Lett. 2020 Feb;19(2):1559-1566. doi: 10.3892/ol.2019.11220. Epub 2019 Dec 16. PMID: 31966081; PMCID: PMC6956423.
430. Lombardi A, Russo M, Luce A, Morgillo F, Tirino V, Misso G, Martinelli E,
Troiani T, Desiderio V, Papaccio G, Iovino F, Argenziano G, Moscarella E,
Sperlongano P, Galizia G, Addeo R, Necas A, Necasova A, Ciardiello F, Ronchi A, Caraglia M, Grimaldi A. Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic
Variants in Cancer. High Throughput. 2020 Feb 11;9(1):4. doi: 10.3390/ht9010004. PMID: 32054005; PMCID: PMC7151067.
431. Di Martino MT, Meschini S, Scotlandi K, Riganti C, De Smaele E, Zazzeroni F, Donadelli M, Leonetti C, Caraglia M. From single gene analysis to single cell
profiling: a new era for precision medicine. J Exp Clin Cancer Res. 2020 Mar
5;39(1):48. doi: 10.1186/s13046-020-01549-3. PMID: 32138788; PMCID: PMC7059661.

432. Zappavigna S, Cossu AM, Grimaldi A, Bocchetti M, Ferraro GA, Nicoletti GF, Filosa R, Caraglia M. Anti-Inflammatory Drugs as Anticancer Agents. Int J Mol
Sci. 2020 Apr 9;21(7):2605. doi: 10.3390/ijms21072605. PMID: 32283655; PMCID: PMC7177823.

433. Ottaiano A, Circelli L, Lombardi A, Scala S, Martucci N, Galon J, Buonanno
M, Scognamiglio G, Botti G, Hermitte F, Savarese G, D’Amore L, Tatangelo F, Di
Mauro A, Liguori G, Trotta AM, Napolitano M, Capozzi M, Tafuto S, Perri F, La
Rocca A, Caraglia M, Nasti G. Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer. Cell Death Dis. 2020 Apr
24;11(4):275. doi: 10.1038/s41419-020-2480-6. PMID: 32332709; PMCID: PMC7181838. 434. Kawasaki H, Takeuchi T, Ricciardiello F, Lombardi A, Biganzoli E, Fornili M,

De Bortoli D, Mesolella M, Cossu AM, Scrima M, Capasso R, Falco M, Motta G, Motta G, Testa D, De Luca S, Oliva F, Abate T, Mazzone S, Misso G, Caraglia M. Definition of miRNA Signatures of Nodal Metastasis in LCa: miR-449a Targets Notch Genes and Suppresses Cell Migration and Invasion. Mol Ther Nucleic Acids.

Page 38 / 42

Curriculum Vitae

Michele Caraglia

2020 Jun 5;20:711-724. doi: 10.1016/j.omtn.2020.04.006. Epub 2020 Apr 21. PMID: 32402942; PMCID: PMC7218231.
435. Takeuchi T, Kawasaki H, Luce A, Cossu AM, Misso G, Scrima M, Bocchetti M, Ricciardiello F, Caraglia M, Zappavigna S. Insight toward the MicroRNA Profiling

of Laryngeal Cancers: Biological Role and Clinical Impact. Int J Mol Sci. 2020 May 24;21(10):3693. doi: 10.3390/ijms21103693. PMID: 32456271; PMCID: PMC7279294.
436. Ferraro MG, Piccolo M, Misso G, Maione F, Montesarchio D, Caraglia M, Paduano L, Santamaria R, Irace C. Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems. Cells. 2020 Jun 5;9(6):1412. doi: 10.3390/cells9061412. PMID: 32517101; PMCID: PMC7349411.

437. Correale P, Saladino RE, Giannarelli D, Giannicola R, Agostino R, Staropoli N, Strangio A, Del Giudice T, Nardone V, Altomonte M, Pastina P, Tini P, Falzea AC, Imbesi N, Arcati V, Romeo G, Caracciolo D, Luce A, Caraglia M, Giordano A, Pirtoli L, Necas A, Amler E, Barbieri V, Tassone P, Tagliaferri P. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade. J Immunother Cancer. 2020 Jun;8(1):e000733. doi: 10.1136/jitc-2020-000733. PMID: 32554614; PMCID: PMC7304840.

438. Ottaiano A, Caraglia M. MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Letter.
Clin Cancer Res. 2020 Jul 1;26(13):3493-3494. doi: 10.1158/1078-0432.CCR-19-3991. PMID: 32611627.

439. Campani V, Zappavigna S, Scotti L, Abate M, Porru M, Leonetti C, Caraglia M, De Rosa G. Hybrid lipid self-assembling nanoparticles for brain delivery of microRNA. Int J Pharm. 2020 Oct 15;588:119693. doi: 10.1016/j.ijpharm.2020.119693. Epub 2020 Aug 2. PMID: 32755686.

440. Sciammarella C, Luce A, Riccardi F, Mocerino C, Modica R, Berretta M, Misso G, Cossu AM, Colao A, Vitale G, Necas A, Fedacko J, Galdiero M, Correale P, Faggiano A, Caraglia M, Capasso A, Grimaldi A. Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to

Page 39 / 42

Curriculum Vitae

Replace with First name(s) Surname(s)

Everolimus. Front Oncol. 2020 Jul 7;10:1047. doi: 10.3389/fonc.2020.01047. PMID: 32766136; PMCID: PMC7379869.
441. Correale P, Saladino RE, Giannarelli D, Sergi A, Mazzei MA, Bianco G, Giannicola R, Iuliano E, Forte IM, Calandruccio ND, Falzea AC, Strangio A, Nardone V, Pastina P, Tini P, Luce A, Caraglia M, Caracciolo D, Mutti L, Tassone P, Pirtoli L, Giordano A, Tagliaferri P. HLA Expression Correlates to the Risk

of Immune Checkpoint Inhibitor-Induced Pneumonitis. Cells. 2020 Aug
25;9(9):1964. doi: 10.3390/cells9091964. PMID: 32854442; PMCID: PMC7564884. 442. Martellucci S, Orefice NS, Angelucci A, Luce A, Caraglia M, Zappavigna S. Extracellular Vesicles: New Endogenous Shuttles for miRNAs in Cancer Diagnosis and Therapy? Int J Mol Sci. 2020 Sep 4;21(18):6486. doi: 10.3390/ijms21186486. PMID: 32899898; PMCID: PMC7555972.
443. Orefice NS, Guillemot-Legris O, Capasso R, Bottemanne P, Hantraye P, Caraglia M, Orefice G, Alhouayek M, Muccioli GG. miRNA profile is altered in a modified EAE mouse model of multiple sclerosis featuring cortical lesions.
Elife. 2020 Sep 17;9:e56916. doi: 10.7554/eLife.56916. PMID: 32940597; PMCID: PMC7498263.
444. Onofrio L, Caraglia M, Facchini G, Margherita V, Placido S, Buonerba C. Toll- like receptors and COVID-19: a two-faced story with an exciting ending. Future
Sci OA. 2020 Jul 30;6(8):FSO605. doi: 10.2144/fsoa-2020-0091. PMID: 32974046; PMCID: PMC7434222.
445. Correale P, Caracciolo M, Bilotta F, Conte M, Cuzzola M, Falcone C, Mangano C, Falzea AC, Iuliano E, Morabito A, Foti G, Armentano A, Caraglia M, De Lorenzo A, Sitkovsky M, Macheda S. Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia. PLoS One. 2020 Oct 8;15(10):e0239692. doi: 10.1371/journal.pone.0239692. PMID: 33031409; PMCID: PMC7544127.
446. Mele L, Del Vecchio V, Marampon F, Regad T, Wagner S, Mosca L, Bimonte S, Giudice A, Liccardo D, Prisco C, Schwerdtfeger M, La Noce M, Tirino V, Caraglia
M, Papaccio G, Desiderio V, Barbieri A. β<sub>2</sub>-AR blockade potentiates MEK1/2 inhibitor effect on HNSCC by regulating the Nrf2-mediated defense mechanism. Cell Death Dis. 2020 Oct 13;11(10):850. doi: 10.1038/s41419-020-03056-x. PMID: 33051434; PMCID: PMC7555890.

Page 40 / 42

Curriculum Vitae

Michele Caraglia

447. Ottaiano A, Caraglia M, Di Mauro A, Botti G, Lombardi A, Galon J, Luce A, D’Amore L, Perri F, Santorsola M, Hermitte F, Savarese G, Tatangelo F, Granata
V, Izzo F, Belli A, Scala S, Delrio P, Circelli L, Nasti G. Evolution of
Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. Cancers (Basel). 2020 Oct 21;12(10):3073. doi: 10.3390/cancers12103073. PMID: 33096795; PMCID: PMC7589866.

448. Mosca L, Vitiello F, Coppola A, Borzacchiello L, Ilisso CP, Pagano M,
Caraglia M, Cacciapuoti G, Porcelli M. Therapeutic Potential of the Natural Compound S-Adenosylmethionine as a Chemoprotective Synergistic Agent in Breast, and Head and Neck Cancer Treatment: Current Status of Research. Int J Mol Sci. 2020 Nov 13;21(22):8547. doi: 10.3390/ijms21228547. PMID: 33202711; PMCID: PMC7697526.
449. Correale P, Giannicola R, Saladino RE, Nardone V, Pirtoli L, Tassone P, Luce A, Cappabianca S, Scrima M, Tagliaferri P, Caraglia M. On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint
blocking mAbs in small cell lung cancer. Transl Lung Cancer Res. 2020 Oct;9(5):1712-1719. doi: 10.21037/tlcr-20-536. PMID: 33209592; PMCID: PMC7653153.
450. Pagano M, Mosca L, Vitiello F, Ilisso CP, Coppola A, Borzacchiello L, Mele L, Caruso FP, Ceccarelli M, Caraglia M, Cacciapuoti G, Porcelli M. Mi-RNA-888-5p Is Involved in S-Adenosylmethionine Antitumor Effects in Laryngeal Squamous Cancer Cells. Cancers (Basel). 2020 Dec 7;12(12):3665. doi: 10.3390/cancers12123665. PMID: 33297397; PMCID: PMC7762311.
451. Ferro M, Lucarelli G, Crocetto F, Dolce P, Verde A, La Civita E, Zappavigna
S, de Cobelli O, Di Lorenzo G, Facchini BA, Scafuri L, Onofrio L, Porreca A,
Busetto GM, Sonpavde G, Caraglia M, Klain M, Terracciano D, De Placido S, Buonerba C. First-line systemic therapy for metastatic castration-sensitive
prostate cancer: An updated systematic review with novel findings. Crit Rev
Oncol Hematol. 2020 Dec 13;157:103198. doi: 10.1016/j.critrevonc.2020.103198. Epub ahead of print. PMID: 33316417.
452. Coppola A, Ilisso CP, Stellavato A, Schiraldi C, Caraglia M, Mosca L, Cacciapuoti G, Porcelli M. S-Adenosylmethionine Inhibits Cell Growth and
Migration of Triple Negative Breast Cancer Cells through Upregulating MiRNA-34c

Page 41 / 42

Curriculum Vitae

Replace with First name(s) Surname(s)

and MiRNA-449a. Int J Mol Sci. 2020 Dec 30;22(1):286. doi: 10.3390/ijms22010286. PMID: 33396625; PMCID: PMC7795242.

H Index: 70 (Google Scholar) 59 (Scopus) Impact factor: about 10000

BOOK CHAPTERS

1) M. Caraglia, G. Meo, A. Budillon: “Fattori predittivi di tossicità correlata alla Chemioterapia: Carcinoma del Colon-Retto” in G. Tonini: “I fattori predittivi in oncologia” Il Pensiero Scientifico Editore, 2005.

2) M. Caraglia, A. Catalano, M. Marra, A. Budillon, A. Procopio: “Oxidative stress and activation of survival pathways as a basis for mesothelioma pathogenesis: new perspectives for experimental therapy” in A. Baldi ed.: “Mesothelioma: from bench side to the clinic” Nova Science Publishers, Inc.Hauppauge, NY. 2007.

3) A. Budillon , M Caraglia, E Di Gennaro, M Marra. “L’Apparato Respiratorio” in Balestrieri C. et al.eds. “Diagnostica Molecolare nella Medicina di Laboratorio”, pp. 155-179. Piccin, Italy 2008

4) M. Caraglia and M. Marra. Cura del capitolo 13 “Il Metabolismo dei Lipidi II: vie Metaboliche di Lipidi particolari” dell’edizione italiana del Textbook of biochemistry. With clinical correlations di Devlin (Idelson – Gnocchi 6° edizione)

5) M. Caraglia, G. F. Nicoletti, A. Lombardi, G. Botti e R. Franco capitolo 3 in A . Baldi and al. Skin Cancer:A Pratical Approach “Cutaneous Squamous Cell Carcinoma: Focus on Biochemical and Molecular Characteristics” pp 29-57 Humana Press

6) R. Franco, A.M. Anniciello, G. Botti, M. Caraglia e A. Luce capitolo 5 in A . Baldi and al. Skin Cancer: A Pratical Approach “Basal Cell Carcinoma : Molecular and Pathological Features” pp 75-88 Humana Press

7) R. Franco, M.E Errico, F. Zito Marino, A.M. Anniciello, G. Botti, M. Caraglia e A. Grimaldi “Skin Adnexal Tumours: A LArge Spectrum of Clinic- Pathological Lesions” pp 89-108 Humana Press

PATENTS
1. E. Novellino, P. Grieco, M. Caraglia, A. Budillon, R. Franco, SR Addeo. Impiego di ligandi di natura peptidica e non peptidica del recettore

UT dell’Urotensina-II quali marcatori di differenziazione del carcinoma prostatico umano. FI2007A000032
2. E. Novellino, P. Grieco, M. Caraglia, A. Budillon, R. Franco, SR Addeo. Use of non peptidic and peptidic ligands or immunodetection of the

receptor for urotensin II for the definition of both differentiation and prognosis of human prostate adenocrarcinoma. PCT/EP2008/051541
3. M. Caraglia, G. De Rosa, A. Abbruzzese, M.I. La Rotonda, C. Leonetti, P. Tassone, G. Salzano, M. Marra. Uso dell’acido zoledronico per

la preparazione di formulazioni farmaceutiche per il trattamento del cancro della prostata e del mieloma multiplo. FI2009A000190
4. M. Caraglia, G. De Rosa, A. Abbruzzese, M.I. La Rotonda, C. Leonetti, P. Tassone, G. Salzano, M. Marra. Nanoparticelle

autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori. FI2010A000206.

5. Dipartimento di Medicina Sperimentale della Seconda Università di Napoli, A. Abbruzzese, M. Caraglia, G. De Rosa, M. I. La Rotonda, L. Luongo, G. Salzano, M. Marra, E. Palazzo, F. Rossi. Uso di bisfosfonati per la preparazione di formulazioni farmaceutiche per il trattamento dei sintomi associati a dolore neuropatico. NA2010A000046 del 28.09.2010

6. De Rosa G., Caraglia M., Tassone P., La Rotonda M.I., Abbruzzese Saccardi A., Salzano G., Marra M., Leonetti C. Self-assembling nanoparticles for the release of bisphosphonates in the treatment of human cancers. [WO2012042024].PCT/EP2011/067119

7. De Rosa G., Tassone P., Caraglia M., Tagliaferri P. “Formulazione costituita da SNALP contenente pre-miR34a utile per il trattamento del mieloma multiplo“FI2012A000025 del 14/02/2012